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BIOCHEMICAL EVALUATION OF LIGNIN-LIKE MOLECULES 
 
By Jay N Thakkar, PhD 
 
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2011 
 
Director: Dr. Umesh R. Desai 
Professor, Department of Medicinal Chemistry 
 
Current anticoagulants carry a serious risk of bleeding complications. In addition, narrow 
therapeutic index, drug interactions, immunological reactions, toxicity and high cost to benefit 
ratio limits the effective use of these drugs in patients with thrombotic conditions. 
xix 
 
 
 
Heparin is the most widely used anticoagulant. We hypothesized that one of the major 
drawback of heparins, its non-specific interaction with the plasma proteins arises as a result of 
negative charges. To reduce these non-specific interactions, our laboratory designed sulfated low 
molecular weight lignin (LMWL) like biomacromolecules, which were found to be direct 
inhibitors of thrombin and factor Xa, acting through a unique exosite-2 mediated process.  
To elucidate the structural basis of this mechanism, we studied unsulfated and size 
fractionated LMWLs. Detailed enzyme inhibition studies with sulfated and unsulfated LMWLs 
of ferulic and caffeic acid oligomers revealed that sulfation was not absolutely critical for dual 
inhibition property and smaller oligomers can yield a potent anticoagulant. Mechanistically, 
unsulfated LMWLs retained exosite-2 mediated inhibition mechanism. A major advantage 
expected of the unsulfated LMWLs is the possibility that orally bioavailable anticoagulants may 
become possible.  
To identify target specific structures within the heterogeneous population of sulfated 
LMWLs, we prepared sulfated β-O-4-linked oligomer using chemical synthesis. Enzyme 
inhibition studies revealed that the sulfated β-O-4 LMWL were highly selective direct inhibitors 
of thrombin. These results show for the first time that specific structural features on LMWL 
scaffold dictate inhibition specificity. Studies in plasma and blood display highly promising 
anticoagulant profile for further studies in animals.  
To further study the LMWL scaffold as macromolecular mimetic of heparin; we 
investigated their effect in preventing cellular infection by herpes simplex virus-1 (HSV-1). 
Based on previous findings on sulfated lignins a size-dependent study on unsulfated LMWLs 
was done. The unsulfated lignins were found to not only inhibit HSV-1 entry into mammalian 
cells, but were more potent than sulfated lignins. Interestingly, shorter chains were found to be as 
xx 
 
 
 
active as the longer ones, suggesting that structural features, in addition to carboxylate groups, 
may be important. It can be expected that unsulfated lignins also antagonize the entry of other 
enveloped viruses, like HIV-1 and HCV that utilize heparan sulfate to gain entry into cells. The 
results further present major opportunities for developing lignin-based antiviral formulations for 
topical use. 
1 
 
CHAPTER 01 
Introduction 
1.1 Background 
Cardiovascular disease (CVD) is estimated to be responsible for 17.1 million deaths per 
year, making it number one cause of death worldwide.
1-4
 WHO estimates that by 2030, 
the number people dying from CVD, mainly heart disease and stroke is expected to reach 
23.6 million. The advancement of safe and adequate treatment options for thrombotic 
disorders has proven elusive for over half a century. The problem probably lies in the 
complexity of the hemostatic system, which maintains the balance between thrombus 
formation and blood flow primarily through the action of a serine protease known as 
thrombin.
5
 Inhibition of this enzyme would be beneficial for the treatment and prevention 
of a multitude of CVDs.
6-7
 Current therapies reduce the risk of recurrent CVDs but are 
plagued with side effects, dosage maintenance difficulties, and undesirable delivery 
methods.
8
 Consequently, there is significant medicinal potential for the design and 
synthesis of novel anticoagulant agents that are both potent and selective with minimal 
side effects.  
 
1.2 Hemostasis  
The role of hemostasis is to maintain an unimpeded flow of blood and return its fluidity 
following vascular injury.
5,9
 A systematic understanding of the hemostatic system is 
necessary in order to design and develop newer anticoagulant agents. The hemostatic 
system refers to the complex interaction of plasma coagulation and fibrinolytic proteins, 
platelets, and the blood vasculature.
10-11
 Hemostasis is further sub-categorized into; 1) 
2 
 
Primary hemostasis – in this a clot is formed at the site of injury through aggregation of 
platelets. 2) Secondary hemostasis – the platelet plug formed strengthens through tandem 
fibrin meshwork forming via the complex coagulation cascade. 3) Tertiary hemostasis – 
the clot retracts and is slowly lysed by plasmin.
12
 The hemostatic system is stimulated 
through the activation of the fVII-tissue factor complex and the aggregation of circulating 
platelets.
5,10
 The two responses combined produce the hemostatic plug. The controlled 
occurrence of these discrete responses require coordination between the platelet and 
coagulation cascade, which is attained through the employment of the plasma protease, 
thrombin.
13
 Thus, thrombin is the vital link between these two systems. 
 
1.3 Pathology of Improperly Regulated Hemostasis 
Hemostasis is a complex balance of events which, if improperly regulated can lead to 
various complications during an injury. Inadequacies in hemostasis can lead to 
hemorrhage, while inappropriate or excessive hemostasis can lead to thrombosis.
14-19 
Both of these are complex in nature that occur in the coagulation and fibrinolytic 
systems. In view of the fact that the coagulation and fibrinolytic system are inter-linked, 
any distortion of the coagulation system is amplified by the fibrinolytic system. 
 
Technically hemorrhage signify bleeding. Apart from trauma, hemorrhage can occur due 
to several factors; 1) intravascular changes or decrease in the clotting factors, 2) 
intramural changes caused due to aneurysms or arteriovenous malformation, and 3) 
extravascular changes caused due to H. pylori infection, brain tumor or abscess.
14-15
 
3 
 
Other factors that can cause bleeding are drugs such as NSAIDs, which inhibit production 
of thromboxane and activation of platelets.
16-17
 
 
Thrombosis implies formation of a blood clot, which eventually blocks the circulation of 
blood flow. Thrombosis can occur due to several factors; 1) genetic deficiencies or 
autoimmune disorders leading to hypercoagulability, 2) exposure of tissue factor (TF) to 
the blood coagulation system caused during trauma, surgery or infection and 3) disturbed 
blood flow, which can occur due to long periods of sedentary behavior (eg: traveler’s 
thrombosis), atrial fibrillation, venous stasis, obstruction of blood flow, certain type of 
cancers and cancer therapies. 
18-19
 
 
A large percentage of population is at risk of developing a pathological thrombus whether 
in the form of a stroke, venous thromboembolism, or arterial thrombosis.
20
 Generally 
speaking, undesirable clots are a result of unregulated or unwarranted generation of 
thrombin, leading to an increase in thrombin-activable fibrinolysis inhibitor (TAFI) 
activation. Excessive TAFI activation would extenuate fibrinolysis and consequently 
hinder the restoration of blood flow in a timely manner.
21-22
  
 
1.4 The Coagulation Cascade 
The coagulation cascade is a complex ordered set of proteolytic events that occurs in the 
body when a blood vessel is injured (figure 01).
23
 Each enzyme of the coagulation 
pathway is present as a protease zymogen in plasma, which on activation undergoes 
proteolytic cleavage to discharge the active factor from the antecedent molecule.
24
 The 
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activation is functional through a series of positive and negative feedback loops. 
Eventually, the pathway leads to production of thrombin, which promotes fibrin 
formation to form a clot, thereby down regulating the procoagulant activity.
25
 Thrombin 
generation occurs via two pathways, the intrinsic and the extrinsic pathway, which 
converge at fX to a single common pathway resulting in the production of thrombin 
(fIIa). 
26
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 01. Simplified coagulation cascade 
HMWK - high molecular weight kininogen; AT – antithrombin; APC – activate protein C and 
TFPI – tissue factor pathway inhibitor 
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1.4.1 Intrinsic Pathway 
It is also called as the contact pathway, and is less significant and not very well 
understood in terms of its role in hemostasis under normal physiological conditions.
23,27
 
The contact pathway gets its name from the fact that the coagulation system is activated 
to form a clot when blood comes into contact with negatively charged surfaces or with 
sub-endothelial connective tissues.
28
 The first step is binding of fXII (Hageman factor) to 
the sub-endothelial surface followed by an injury. Prekallikrein, and high molecular 
weight kininogen (HMWK) also bind at the surface activating fXII to fXIIa. During this 
activation fXII is cleaved into two chains, which stay connected through a disulfide 
bond.
29
 The lighter of the two chains contain the active site and is termed as the activated 
fXII (fXIIa).
29
 fXII can auto-activate or activate through a feedback mechanism by 
activating prekallikrein thus amplifying the pathway. fXIIa then activates fXI to fXIa in 
presence of HMWK and Ca
+2
 ions secreted from platelets. fXIa in turn catalyzes the 
conversion of fIX to fIXa in presence of Ca
+2 
ions. Eventually, fX is activated to fXa, a 
process that can also occur through the extrinsic pathway. fX activation is brought about 
by a molecular complex containing fIXa, fVIII, Ca
+2 
ions and phospholipids provided by 
the platelet surface, where this reaction usually takes place.
25
 The precise role of fVIII in 
this reaction is not clearly understood. Its presence in the complex is obviously 
indispensable, as seen by the serious consequences of fVIII deficiency experienced by 
haemophiliacs.
30
 fVIII is altered by thrombin, to its activated form, promoting the 
activation of fX. Although the physiological contribution of the contact pathway to 
coagulation remains elusive, recent data suggest that it plays some role in physiological 
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blood coagulation, since mice deficient in fXII have been shown to be protected against 
both stroke and arterial thrombosis.
31
 
 
1.4.2 Extrinsic Pathway 
It is also called as the TF pathway and is the major physiological pathway for fibrin 
formation.
23,27
 It provides a swift response to tissue injury, generating fXa almost 
instantaneously, as opposed to the seconds or even minutes required for the intrinsic 
pathway to activate fX.
32
 The main function of the extrinsic pathway is to enhance the 
activity of the intrinsic pathway.
32
 The pathway sets in at the site of injury in response to 
the release of the procoagulant, TF, which is present in most human cells bound to the 
cell membrane.
23,27,32
 The activation process for TF is not clearly understood. On 
activation, TF binds rapidly to fVII activating it to form a TF + fVIIa complex, which in 
presence of Ca
+2 
ions and phospholipids instantaneously activates fIX and fX. fXa can 
further activate fVII, which forms the link between the two pathways along with fIX 
activation.
25
 
 
1.4.3 The Common Pathway 
This is the most crucial step in the coagulation cascade, which harbors fX (fXa) and is 
responsible for thrombin generation.
23,26
 Through the sequential activation of several 
zymogens in the extrinsic and the intrinsic pathway, prothrombin (fII) is ultimately 
activated via fXa and the prothrombinase complex (fVa, prothrombin, phospholipids and 
Ca
+2 
ions). The prothrombinase complex activates prothrombin to thrombin (fIIa) 
300,000-fold more efficiently that fXa alone.
33
 The fundamental role of thrombin is 
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conversion of fibrinogen (fI) to fibrin (fIa) to form a fibrin mesh-work, which are 
eventually cross-linked by fXIIIa to form a stable fibrin clot.
25-26
 In addition, thrombin 
also activates fVIII, fV and their inhibitor, protein C (1000-fold higher in presence of 
thrombomodulin) and FXIII.
34
 Following activation of the either pathways the 
coagulation cascade is maintained in a prothrombotic state by the persistent activation of 
fVIII and fIX to form the tenase complex, until its down-regulation by the anticoagulant 
pathways. The three major endogenous anticoagulants in our body are antithrombin III 
(AT), activated protein C (APC) and tissue factor pathway inhibitor (TFPI).
35
 
 
1.5 Fibrinolysis 
The clot formed as a result of an injury does not stay for ever. Gradually, the blood clot is 
reorganized and reabsorbed by a process termed fibrinolysis (figure 02).
23
 This is 
accomplished by a non-specific proteolytic enzyme, plasmin. Tissue-type plasminogen 
activator (tPA) secreted from endothelial cells and urokinase activates the zymogen 
plasminogen (Pg) to form the serine protease plasmin, which is responsible for degrading 
the fibrin clot and restoring the blood fluidity.
36-37
 Analogous to the coagulation cascade a 
series of stepwise events occur during fibrinolysis, which involves a fine balance between 
plasmin/antiplasmin and thrombin/thrombomodulin activities.
38
 In essence, coagulation 
and fibrinolysis systems work in cooperation to maintain hemostasis at the site of injury 
while ensuring fluidity of the blood elsewhere. 
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Figure 02. Fibrinolysis mechanism 
tPA – tissue-type plasminogen activator; TAFI – thrombin-activatable fibrinolysis inhibitor 
Blue arrows denote stimulation and red lines inhibition. 
 
 
1.6 Thrombin and the Coagulation System 
Thrombin has been termed as the master regulator enzyme in blood coagulation.
39
 It is 
the last enzyme in the coagulation cascade and its ultimate product is a formation of a 
stable clot.
26
 Thrombin, a trypsin-like serine protease ensues from the circulating 
zymogen precursor protein, prothrombin.
40-41
 Prothrombin cleaves to form an enzyme 
with an overall ellipsoid-like structure comprising of a small A-chain and a catalytic B-
chain.
42-43
 The catalytic activity of thrombin is not only dictated by its active site but also 
by recognition sites (exosite-1 and exosite-2), which modulate the specificity of the 
enzyme.
40,44
 Understanding of the interactions between thrombin and its substrate is 
crucial in the identification and design of novel medicinal agents that would interact and 
regulate the activity of the enzyme (figure 03). An interesting aspect of thrombin in the 
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hemostatic system is its contrasting dual nature where it acts as both an anticoagulant and 
a pro-coagulant.
5
 Activity of thrombin is primarily controlled by two systems; 1) AT and 
2) protein C and protein S.   
 
The major regulator of thrombin activity is the plasma serine protease inhibitor (SERPIN) 
AT. AT directly interacts with the active site of thrombin as well as the other major 
coagulation enzymes (factors Xa, VIIa, IXa, XIa, XIIa, and plasma kallikrein) hampering 
the formation of both the tenase and prothrombase complexes.
5,26
 Heparin cofactor 
accelerates the inhibition of thrombin by AT with a 1,000-fold greater potency.
5,45
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 03. Critical role of thrombin 
APC – activate protein C; PAR – protease activate receptor.  
Blue arrows denote stimulation and red inhibition. 
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Protein C is activated by thrombin to activated protein C (APC), which is further 
enhanced in presence of endothelial protein C receptors and thrombomodulin. APC 
inactivates fVa and fVIIIa, two cofactors of thrombin, thus reducing the rate of thrombin 
formation.
5,45
 Protein S acts as a cofactor for APC, and serves as APC’s receptor to 
localize its inhibitory role. The anticoagulant role of thrombin is dependent on a finite 
number of thrombomodulin binding sites.
45-46
 When these sites are exceeded, it converts 
thrombin into a physiologic pro-coagulant enzyme. Heparin cofactor II, a SERPIN is a 
specific thrombin inhibitor whose activity is potentiated by the glycosaminoglycan 
(GAG), dermatan sulfate.
47
 
 
Although the enzymatic role of thrombin in the hemostatic process is significant and 
impressive, it also has many other biological roles that are far more intricate.
48-49
 Some of 
these include the role of thrombin in platelet activation and aggregation.
50-51
 Two 
substrates on human platelets, protease-activated receptors 1 and 4 lead to platelet 
activation when stimulated.
52-53
 Platelets have the ability to aggregate at the site of injury 
which leads to the development of acute myocardial syndrome and coronary artery 
occlusion. The non-hemostatic role involves the stimulation of chemotaxis of white blood 
cells (WBC), generation and discharge of cytokines, fibroblast proliferation and 
mitogenesis.
54-56 
Effects of thrombin on endothelial cells leads to the release of a variety 
of biological mediators.
49,57-58
 Although not well defined, evidence of a role in cancer cell 
adhesion has been speculated.
59
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1.7 Anticoagulant Treatment  
Thrombin plays a crucial role in coagulation of blood, hence prophylaxis or treatment of 
thromboembolic disorders aim to block thrombin generation or inhibit thrombin’s 
activity. There are two primary approaches employed by drug researchers in designing 
anticoagulants; 1) to directly inhibit thrombin with active site inhibitors or allosteric 
modulators such as hirudin  and 2) to impede formation of thrombin by inhibiting the 
precursors in the coagulation cascade or by disrupting the metabolic pathway (indirect 
inhibition) such as heparin.
60-61
  
 
Indirect inhibitors such as coumarin, dicoumarol, and warfarin are vitamin-K antagonists 
and have been some of the most commonly administered anticoagulants (figure 04). 
These agents work by inhibiting synthesis of biologically active forms vitamin-K 
dependent clotting factors (fII, fVII, fIX, fX, protein C and protein S) of the coagulation 
system.
62-63
 Carboxylation of these coagulation factors enhances their binding to  
 
 
 
 
 
 
Figure 04. Vitamin-K antagonist indirect inhibitors of thrombin  
A) coumarin and B) warfarin 
 
phospholipid surfaces, thereby accelerating
 
blood coagulation.
64
 For example, warfarin 
inhibits the vitamin-K epoxide reductase, which hampers the formation of reduced 
A)                                               B) 
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vitamin-K required for γ-carboxylation of these clotting factors.64-65 Heparin and low 
molecular weight derivatives of heparin (LMWH) are other indirect inhibitors frequently 
used in clinical settings (figure 05).
66
 Heparin is a sulfated GAG produced by mast cells, 
which activates the endogenous anticoagulant, AT.
67
 Specific sequences in heparin and 
LMWH bind AT and bring about a conformational change in the endogenous inhibitor 
that leads to 1,000-fold acceleration in the rate of AT activity.
67-68
 This is a two step 
process, which includes accelerated inhibition of fXa followed by a bridging mechanism 
of heparin, which brings thrombin and AT into close proximity.
62,69
 The mechanism of 
inhibition varies slightly for each protease.  
 
Figure 05. AT activator indirect inhibitors of thrombin 
Heparin and low molecular weight heparins (LMWH) 
 
 
Direct thrombin inhibitors such as hirudin, recombinant hirudin (lepirudin and desirudin) 
and bivalirudin bind at the active site and exosite I; whereas, argatroban and ximelagatran 
bind exclusively at the active site of thrombin bringing about disruption of the catalytic 
arsenal leading to cessation of thrombin activity (figure 06).
70-73
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Figure 06. Direct inhibitors of thrombin 
A) Argatroban and B) Ximelagatran 
 
 
1.8 Medical Role of Anticoagulant Therapy 
The most promising application of a novel anticoagulant agent would be prevention of 
acute coronary syndrome (ACS), stroke and venous thromboembolism (VTE). ACS is an 
umbrella term covering a spectrum of clinical conditions ranging from unstable angina to 
acute myocardial infarction.
74-75
 About every 26 seconds, an American encounters a 
coronary event, and about every minute one will die as a result of an acute thrombus 
obstructing the coronary artery.
76
 A stroke, sometimes called a brain attack, occurs when 
a clot blocks the blood supply to the brain or when a blood vessel in the brain bursts.
77
 
Approximately 25% of all strokes are associated with aberrations in the cardiovascular 
system.
78
 These abnormalities lead to the development of a secondary embolus that 
blocks the cerebral circulation resulting in ischemia and neuronal damage.
79-80
 
Cardioembolic strokes can be treated with anticoagulants following atrial fibrillation, 
intracardial thrombus or endocarditis.
81
 About every 40 seconds someone in the US has a 
A)                           B) 
 
14 
 
stroke and every 4 minute someone dies of stroke.
76
 VTE, 3
rd
 most common cardio 
vascular (CV) illness refers to a number of medical conditions that result from abnormal 
thrombosis including deep vein thrombosis (DVT) and pulmonary embolism (PE).
62
 
About 1 million people are affected by VTE in the US alone.
77
 VTE is caused by three 
major factors: blood hypercoagulability (excessive clotting), blood-flow stasis 
(immobility), and vessel wall damage (atherosclerosis).
62
 Therefore, by modulating the 
activity of the hemostatic system, we can attempt to treat and prevent these serious and 
often fatal medical conditions. Novel anticoagulants that are safer and effective can 
potentially treat these conditions by inhibiting the circulating detached thrombi in 
patients with high risk factors such as race, hypertension, diabetes, and 
hypercholesterolemia.
78
 Anticoagulant treatment is absolutely requisite in patients with 
predisposition for these conditions. Current available anti-thrombotic treatments require 
constant clinical monitoring due to the variation in individual response to the drugs.
79
 
These remedies minimize the risk of recurrent cardiovascular episodes, but accompany 
the risk of bleeding in part because they act systemically.
79
 A new generation of 
anticoagulants with better efficacy and fewer side effects could potentially revolutionize 
the treatment options for thrombotic disorders. 
 
1.9 Limitations of Current Anticoagulant Therapy 
The current anticoagulant therapies are plagued with several limitations; heparin has poor 
subcutaneous absorption, variable effect due to binding to multiple plasma proteins, and 
the development of thrombocytopenia (decrease in normal levels of platelets).
62-63,80
 
LMWH, synthesized in an effort to improve the bioavailability and overcome the non-
15 
 
specific plasma proteins interaction must be administered subcutaneously limiting their 
use for outpatient therapy, in addition the patient needs to be monitored on regular 
basis.
63,80
 Smaller molecules and peptide derivatives suffer a set back due to one or 
several of the following factors; drug-drug, drug-food interactions, narrow therapeutic 
window, significant bleeding risk and inability to inhibit clot bound thrombin.
81
 The need 
to develop highly desirable anticoagulants and an extensive knowledge of the coagulation 
cascade has guided the researchers to focus their attention on the common pathway of the 
coagulation system. In theory, any single enzyme in the coagulation cascade could be 
targeted to bring about the anticoagulation effect. However, fXa and thrombin, that are 
common to both the intrinsic and the extrinsic pathway, can be targeted resulting in a 
more effective anticoagulant.
82
 Designing direct inhibitors of fXa appears to be an 
improved strategy to eliminate most of the side effects of current anticoagulants and 
make it viable to inhibit both the circulating as well as platelet bound fXa without 
affecting the platelet function.
83
 Further, selective direct inhibitors of thrombin called as 
direct thrombin inhibitors (DTIs) can be designed to inhibit the free circulating as well as 
the clot bound thrombin.
63,84
 Inhibitors of thrombin and fXa are fertile areas of 
exploration and are further advanced in development than most other candidates.
85-86
  
 
1.10 Direct fXa Inhibitors  
The amount of an activated coagulation factor produced from
 
its inactive precursor 
amplifies at each stage of the coagulation
 
cascade. Consequently, targeting fXa in the 
common pathway could
 
be an effective approach for developing newer anticoagulants 
(figure 07).
87
 In addition, fXa is known to be the primary
 
site of amplification; one 
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of ~1000 thrombin molecules.
88
 Currently 
available fXa inhibitor work through AT mediation, hence called indirect inhibitors 
(Fondaparinux and Idraparinux).
89-90
 Direct fXa inhibitors (eg: rivaroxaban and apixaban) 
are AT independent and are 10,000 fold more selective for fXa over other related 
proteinases (figure 08).
91-93
 fXa inhibition results in down regulation of thrombin 
formation (not thrombin activity) via both the pathways by blocking the interaction with 
prothrombin.
94
 This allows the circulating thrombin to perform its vital functions, thus 
potentially maintaining
 
hemostasis at sites of hemostatic challenge. Another advantage of 
direct fXa inhibitors is that it inhibits free fXa as well as platelet bound fXa, which is part 
of the prothrombinase complex and clots.
94
 Outside the coagulation system fXa has 
shown to exhibit proinflammatory activity.
95
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 07. Pivotal position of fXa and thrombin in the coagulation cascade and mode of 
action of a few fXa and thrombin inhibitors.  
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Figure 08. Chemical structures of direct fXa inhibitors 
A) Rivaroxaban and B) Apixaban  
 
 
1.11 Direct Thrombin Inhibitors (DTIs) 
Given the fundamental role thrombin plays in vasculature and platelet signaling, it can be 
rationalized that DTIs would have a positive outcome on vascular physiology. The most 
critical aspect related to thrombus formation is the evasion of clot bound active thrombin 
from its inhibitors such as heparin.
96
 Thrombus thus serves as a reservoir of active 
thrombin, which amplifies its own generation by activation of fV, fVIII and fXI.
97
 It can 
further stimulate thrombus growth by locally activating platelets and converting 
fibrinogen to clottable fibrin.
25-26
 It activates fXIII to form stable clots and enhance 
resistance to fibrinolysis.
25-26
 In addition, after discontinuation of heparin therapy, there 
can be a reactivation of the coagulation system as the fibrin-bound thrombin reactivates 
fX within the thrombus, prompting further thrombin generation.
98
 Thrombin inhibition 
could thus lead to multiple effects for anticoagulation. DTIs (hirudin, lepirudin, 
argatroban, dabigatran) require no preceding interaction prior to their action on thrombin 
A)                                                        B) 
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unlike the indirect acting, which require AT mediation (refer figure 07).
70-73
 DTIs put a 
check on thrombin from interacting effectively with its substrates thus prevent fibrin 
formation, obstruct thrombin-mediated feedback activation, delimit thrombus growth, 
inhibit activation of platelet factor 4 (PF4), protein C and many other functions of 
thrombin.
99
  
 
Thrombin also plays an important role in inflammation and cellular proliferation where 
DTIs may represent an adjuvant therapy (figure 09).
100
 DTIs can be univalent (interact 
with one site) or bivalent (interact with 2 sites).
101
 Unlike direct fXa inhibitors DTIs fail 
to block thrombin generation. Both the DTIs and direct fXa inhibitors will provide more 
predictable anticoagulant responses because they are not bound to plasma proteins.  
 
 
 
 
 
 
 
 
 
 
Figure 09. Various functions of thrombin within and outside the coagulation cascade
82
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1.12 Limitations of Current Direct fXa and Thrombin Inhibitors 
DTIs, like hirudin, form a nearly irreversible bond with the enzyme.
71
 An improvement in 
form of bivalirudin acts as a selective and reversible inhibitor of thrombin however; 
problems with parenteral delivery and rapid clearance have limited its use for a wider 
range of conditions.
102
 These issues were addressed by new class of DTIs like 
melagatran, but were unsuitable for oral administration.
103
 A prodrug of melagatran in 
form of ximelagatran had hepatotoxic and adverse cardiac effects.
104
 In late 2010, 
USFDA had approved dabigatran but not without an added caution “life-threatening and 
fatal bleeding”.105 The oral fXa inhibitors have variable and transient effects on the 
prothrombin time.
106
 A potential drawback of the newer anticoagulants is the lack of 
specific antidotes, shorter half life and lack of lab markers to monitor the drug activity.
107
 
Additionally, since there are no routine monitoring tests it will be difficult to determine 
whether suboptimal results are due to failure of therapy or poor patient compliance. It is 
evident that newer agents may change the future of anticoagulation therapy and provide 
improved patient care. With new opportunities will come new challenges, but the benefits 
of new oral anticoagulant offsets any drawbacks. The results of clinical trials with DTIs 
and direct fXa inhibitors validate both thrombin and factor Xa as potential targets, and 
there is no convincing evidence that one target is better than another.
108
 Head-to-head 
comparisons will reveal any meaningful differences in efficacy or safety among the 
newer agents. Such assessment seems unlikely because of potential commercial risks. 
Even if one exhibits the superiority in targeting over the other, the variation will be more 
reflective of the dose and the pharmacological properties of the drugs rather than the drug 
target. 
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1.13 Bifunctional Inhibitors 
From the preceding discussions it is clear that neither the DTIs nor direct fXa inhibitors 
can inhibit both generation and circulating (free and bound) thrombin, the mainstay in the 
formation of a clot. Hence, the theory of bifunctional inhibitors has been conceived, 
which will inhibit both the serine proteases simultaneously in the common pathway. Both 
the proteases can be inhibited by co-administering inhibitors specific for the enzymes. 
This proposition is not cost effective and will require preclinical and clinical trials to 
study drug interactions and side effects.
109
 The other viable way for simultaneous 
inhibition of both the proteases is to design an inhibitor that would directly inhibit both 
thrombin and fXa. Such inhibitors with dual functionality are termed as bifunctional 
inhibitors. Bifunctional inhibitor is not a new concept in the field of anticoagulation, 
UFH inhibits both thrombin and fXa via the AT mediation. The disadvantage UFH 
carries along is its non-specific binding interactions with other proteins in the system 
leading to numerous side effects.
110
 There are no bifunctional anticoagulant drugs on the 
market, though a few are in the drug discovery phase. 
 
1.14 Structure of Thrombin 
Thrombin has distinctive structural features that control specificity. A closer look at the 
surface reveals uneven charge distribution with localized positively and negatively 
charged pockets in (figure 10).
111-112
 There are four distinct binding sites on thrombin as 
depicted in figure 11. These sites recognize a variety of different molecules and present 
the diverse functions of thrombin.
40,44
 All of the physiologic effects of thrombin are a 
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direct result of its catalytic activity.
114
 Substrate specificity, however, is determined by 
several accessory binding domains that exist in clusters.
114
 
 
1.14.1 Active site 
This is the substrate binding site, which also mediates interactions with fibrinogen, 
protein C and AT-III. 
112
 The active site of thrombin is very similar to that of trypsin and 
chymotrypsin.
40-41
 There are deeply situated specificity pocket (S1) that consists of the 
catalytic triad Ser195-His57-Asp102 surrounded by hydrophobic residues at the rim. 
Asp189 lining the S1 pocket electrostatically interacts with cationic substrates. S2 and S3 
pockets are more hydrophobic and acidic respectively while the S4 pocket has a 
preference for aliphatic groups.
112
  
 
 
 
 
 
 
 
 
 
 
Figure 10. Thrombin surface electron density map with electrostatic potentials.
113
  
The more basic the protein surface, the more red that area appears.  
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1.14.2 Exosite I 
Also called as fibrinogen binding site, it is an anionic binding electropositive site.
112
 
Exosite I recognizes carboxyl terminal domain of hirudin, hirudin-like region of PAR-1 
and fifth and sixth EGF-like domains of thrombomodulin.
115
  It is located to the right of 
the thrombin active site cleft, mainly placed on the 70 to 80 loop and bordered by the 37-
loop and segment Lys109-Lys110. In its center, the exposed side chains of Tyr76 and 
Ile82 form a hydrophobic cap, which is surrounded by side chains of several lysines and 
arginines interspersed by a few hydrophobic side chains. The strong positive charge is 
only partially compensated by the acidic residues Glu77 and Glu80 involved in an ionic 
cluster beneath the surface.
112
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Figure 11. Cartoon representation of thrombin showing the four binding sites and different 
molecules recognizing them.
113
 
Heparin binds at the exosite-II, hirudin binds to both the active site and fibrinogen recognition 
site (exosite-I) melagatran and argatroban binds at the active site.  
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1.14.3 Exosite II  
Also called as the heparin binding site, it is the second electropositive, anionic binding 
site located opposite to exosite I.
112
 Exosite II recognizes carboxyl terminal region of B-
chain of thrombin and highly sulfated polysaccharide like heparin and chondroitin sulfate 
of thrombomodulin.
116
 At this surface, a small hydrophobic Leu234-based channel is 
surrounded by basic residues Arg93, Arg101, Arg165, Arg233, Arg126, Lys236, Lys235, 
Lys240, and His91, with most of their side chain charges not compensated by adjacent 
negative charges. This uncompensated strong electropositive charge attracts polyanionic 
molecules like heparin to recognize exosite II.
112
 
 
Both exosites differentially influence the active site and this allosteric effect plays a 
major role in the specificity and reactivity of thrombin towards its macromolecular 
substrates.
117
 Exosites are located at approximately opposite ends of the thrombin 
molecule and approximately 10–20 Å away from the active site.117 
 
1.14.4 Sodium ion binding site 
Na
+
 ion binding site has been confined to a site in the center of the 222 loop situated in a 
solvent-filled cavity behind the S1 specificity pocket located near Asp189.
112
 The bound 
Na
+
 ion, located more than 15 Å away from the catalytic triad, is coordinated in an 
octahedral manner by the carbonyl oxygens of Arg221 and Lys224 and by four internal 
water molecules, and is further stabilized by the negative charges of Asp221 and 
Asp222.
112
 Thrombin has greater catalytic efficiency in the presence of Na
+ 
ions than in 
the absence of Na
+
ions. 
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1.15 Structure of fXa 
The active site of fXa is smaller and less hydrophobic than the active site of thrombin.
118
 
Refer figure 12 for active site of fXa. The active site is divided into four sub-pockets, S1 
to S4. The major component of selectivity and binding is attributed to S1 sub-pocket. The 
S2 sub-pocket is small, shallow, not well defined and it merges with the S4 sub-pocket. 
The S3 sub-pocket is solvent exposed located on the rim of the S1 pocket. The S4 sub-
pocket has three ligand binding domains, namely the hydrophobic enclave, the cationic 
hole and the water site. fXa inhibitors commonly bind in an L-shaped conformation, 
where one group of the ligand occupies the anionic S1 pocket lined by residues Asp189, 
Ser195, and Tyr228, and another group of the ligand occupies the aromatic S4 pocket 
lined by residues Tyr99, Phe174, and Trp228. Typically, a fairly rigid linker group 
bridges these two interaction sites.
118
  
 
 
 
 
 
 
 
 
 
 
Figure 12. Active site of fXa with key residues displayed
113
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1.16 Conclusion 
Normal hemostasis is essential for regulation of blood flow. An improperly regulated 
hemostasis can cause hemorrhage or thrombosis leading to life threatening conditions. 
Thrombosis occurs due to excessive hemostasis and a thrombus thus formed can lead to 
stroke, venous thromboembolism or arterial thrombosis, which are leading causes of 
death worldwide. Thrombus formation is a product of excessive generation of thrombin 
in the coagulation cascade, which in turn is regulated by numerous other coagulation 
enzymes. In the coagulation cascade, activating the AT or inhibiting the up-regulated 
coagulation enzymes in intrinsic and extrinsic pathways can be targeted to indirectly 
impede the formation of thrombin. Current antithrombotic agents that work through 
indirect inhibition prevent the formation of thrombus, thus reducing the risk of recurrent 
cardiovascular events but not without serious side effects. The major set back is the non-
selectivity of these drugs for the target and their inability to inhibit clot bound thrombin. 
Targeting fXa and thrombin, which are common to both the intrinsic and extrinsic 
pathways could result in a better anticoagulant as they would inhibit both free and clot 
bound thrombin. Direct fXa and thrombin inhibitors are fertile areas of research where a 
mono- or bifunctional inhibitors concept has been envisioned but has been largely 
remained unsuccessful in delivering an ideal anticoagulant. Hence, there still exists the 
need to design a potent anticoagulant with minimal side effects.           
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CHAPTER 02 
Identification of an Optimum Size of DHP as a Lead for Structure-based Drug 
Design 
 
2.1 Background 
Hypercoagulability increases the risk of inappropriate or excessive thrombus (blood clot) 
formation resulting in serious disseminated intravascular coagulation (DIC), venous 
thrombosis, thromboembolism, cardiovascular complications, or in some cases multiple 
organ failure.
62,74-75,81
 Current anti-thrombotic therapies are able to reduce the risk of 
recurrent cardiovascular events, but not without serious side effects, the most widespread 
of all being bleeding.
62-63,80
 One of the major reasons for this has been attributed to the 
non-specific binding of these drugs to plasma proteins.
 62-63,80
 The quest to discover more 
cost effective and safer drug has led researchers to explore deeper into understanding the 
specific mechanism and role of each step in the entire coagulation system. Years of 
research and experience has resulted in numerous drugs targeting different and multiple 
coagulation factors, yielding an enhanced perception of the need for development of 
better and efficient drugs. Specifically targeting the common pathway in the coagulation 
cascade is one such fruit of our conception. There are few drugs that specifically act on 
the proteinases, thrombin and fXa in the common pathway but most are in pre-clinical or 
clinical evaluation stage.
70-73,89-93
 These and the ones that are approved continue to inherit 
the complications from their early ancestors. Hence, the need still exists to develop new 
and improved anticoagulant agents that would eliminate the poor traits of their early 
ancestors.  
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Advancement in this direction has been challenging as there are numerous hurdles that 
have been dragging back the entire drug development process. It is important that the 
new drugs reduce excessive bleeding, liver toxicity, inhibit both free and clot-bound 
thrombin. It also necessitates investigating, which inhibition strategy will yield more 
efficient results in inhibition of thrombin, the ultimate and pivotal proteinase in the 
coagulation cascade. Will inhibiting either of the one proteinase, thrombin and fXa or 
simultaneous inhibition of both would be more efficacious? We don’t know but 
regardless, numerous unanswered questions make the field anticoagulation drug design 
extremely exciting, compelling and challenging. 
 
2.2 Rationale  
All the anticoagulants used today have severe side effects, which may even lead to death. 
The most common anticoagulants used for treatment of thrombotic disorders are heparin 
in its unfractionated form or LMWH and coumarins (warfarin).
63,80
 The heparins have 
risks of bleeding and heparin-induced thrombocytopenia (HIT).
80,118
 Fondaparinux and 
idraparinux, a heparin pentasaccharide; peptidomimetics like agratroban, ximelgatran and 
razaxaban; and hirudins like desirudin and bivalirudin showed to lower these risk factors 
but still possessed the negative traits of their precursors.
70-73,89-93
 In addition, patient 
variability, narrow therapeutic index, drug-interactions, immunological reactions, liver 
toxicity and high cost to benefit ratio limits the effective use of these drugs in patients 
with thrombotic conditions.
81
 
 
29 
 
For more than three decades the anticoagulant drug discovery has revolved around 
heparin and its derivatives, possessing a polysaccharide backbone. Our lab has take a step 
forward in this field by designing molecules, which are not heparin-based (non-
polysaccharide) and they act through either through activation of AT or direct inhibition 
of thrombin and fXa.
119-121
 As a proof of concept our lab has shown that linear 
polyacrylic acids (PAA), which have only the carboxyl functionality, were able to bind 
AT with poor affinities resulting in acceleration of the inhibition of thrombin and fXa.
122-
123
 PAA do not have a polysaccharide backbone and they are devoid of sulfates too! 
Later, to improve the affinity a more rigid skeleton like a phenyl ring with functional 
group that can be derivatized to a sulfated was chosen. The carboxylic functionality was 
retained for it to be amenable for structural modification to be transformed into an orally 
available drug. Based on these features three types of synthetic lignins called as 
dehydropolymers (DHPs) were synthesized enzymatically and later sulfated.
124-125
 The 
three precursors chosen for enzymatic reactions were caffeic acid, ferulic acid and sinapic 
acid and the sulfated polymers were termed as CDS, FDS and SDS. DHPs are structurally 
dissimilar from all the current anticoagulants. The oligomeric, polyanionic, polydisperse 
and micro-heterogeneity of DHPs are similar to that of heparin while the aromatic 
backbone is a distinct feature. All three DHPs showed direct dual inhibition of thrombin 
and fXa through exosite-2 mediation on thrombin.
123-124
 CDS was the most potent of the 
3 DHPs and SDS the least. It has also been shown that the unsulfated DHPs were a 
weaker anticoagulant as compared to its sulfated counterpart.
123
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DHPs as a dual inhibitor were completely a new class of anticoagulant and it was 
imperative to determine what in this mixture could have dictated the activity. This 
inspiration comes from heparin where a specific sequence such as the pentasaccharide 
dictates its activity as an anticoagulant (figure 13). To elucidate this aspect we conducted 
chain length dependence studies on our sulfated and unsulfated DHPs. This chapter talks 
about the importance of the sulfates groups in context of our DHPs and the effective size 
of a working lead molecule, which would be a more potent anticoagulant possibly 
carrying fewer side effects.  
 
 
 
 
 
 
Figure 13. Structure of  pentasaccharide binding sequence. 
 
 
2.3 Experimental Methods 
2.3.1 Proteins, biologicals and chemicals 
Horseradish peroxidase (HRP) with activity of 250–600 330 U/mg (Sigma, St. Louis, 
MO). Human plasma proteinases, fXa, and α-thrombin (Haematologic Technologies, 
Essex Junction, VT). Chromogenic substrates purchased from American Diagnostica 
(Greenwich, CT): Spectrozyme fXa (Methoxycarbonyl-Dcyclohexylglycyl-Gyl-Arg-p-
nitroanilide) Spectrozyme TH (H-Dhexahydrotyrosol-Ala-Arg-p-nitroanilide). Stock 
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solutions of proteins were prepared as follows: For fXa 20 mM Sodium phosphate buffer, 
pH 7.4, 0.1mM EDTA, 0.1% PEG 8000 For thrombin 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl and 2.5 mM CaCl2, 0.1% PEG 8000. Pooled citrated human 
plasma for coagulation time assays (Valley Biomedical Winchester, VA). Activated 
partial thromboplastin time reagent containing ellagic acid (APTT-LS), thromboplastin-D 
and 25 mM CaCl2 (Fisher Diagnostics Middletown, VA). Competitive ligands used - 
Exosite 1 ligand Tyr63-sulfated hirudin-(54-65) labeled with 5-(carboxy)fluorescein 
([5F]-Hir[54-65](SO3-)). Exosite 2 ligand unfractionated porcine heparin (Sigma-Aldrich 
St. Louis, MO). 30% hydrogen peroxide, TEAST complex, ferulic acid (FA) and caffeic 
acid (CA) were from Sigma (St. Louis, MO). Enoxaparin (MR 4,500) (Aventis 
Pharmaceuticals). All other chemicals were of analytical reagent grade from either 
Aldrich Chemicals (Milwaukee, WI) or Fisher (Pittsburgh, PA) and used without further 
purification. 
 
2.3.2 Oxidative coupling and sulfation of 4-hydroxycinnamic acid derivatives 
The DHPs of CA and FA were prepared by the so-called ‘zutropfverfahren’ procedure. 
Briefly, in a three-neck flask slow addition of 200mL CA or FA (25mM in 10mM sodium 
phosphate buffer pH 8.0) and 100mL H2O2 (75mM in the same buffer) to a 50mL 
solution of HRP (10mg in the same buffer) was carried out at room temperature (RT) and 
in dark over a period of 5 hours. Three additional aliquots of H2O2 (75 mM) were added 
over the next 72 h. At the end of polymerization the solution was freeze-dried, 
redissolved and desalted to obtain the CD and FD polymers.  
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DHPs were sulfated with TEAST complex. Briefly, the lyophilized DHP sample (50 mg) 
was dissolved in dry DMF (15 mL) containing TEAST (200 mg) and stirred for 24 h at 
60 °C. After the removal of most of the DMF in vacuo, the remaining product was taken 
up in 30% aqueous sodium acetate, the sodium salt precipitated using ~10 volume of cold 
ethanol. The precipitated product was further purified with dialysis using Amicon dialysis 
membrane (MWCO 3-30K).  
 
2.3.3 Fractionation of CD and FD using centrifugal filtration  
The polymerization reaction mixture was dissolved in deionized water and filtered 
through Millipore filter (NMWC 30 kDa) at 4000 g. Filtration was continued until the 
retentate volume was approximately 200 μL. This process was repeated five more times 
and the final retentate was labeled as F30 fraction. The filtrates from the above process 
were pooled, lyophilized, redissolved in deionized water and then further fractionated in 
the manner described above using a 10 kDa filter. The retentate so obtained was labeled 
as F10 fraction. This process was repeated to obtain F5 and F3 fractions using 5 and 3 
kDa membranes. The retentates were collected and lyophilized to obtain four fractions in 
yields of 15-20, 5-8, 3-5, and 1-2%, respectively. 
 
2.3.4 Sulfation of the DHP fractions 
All the DHP fractions were sulfated using triethylamine–sulfur trioxide complex. Briefly, 
each fraction of DHP sample (50 mg) was dissolved in dry DMF (15 mL) containing 
triethylamine–sulfur trioxide complex (200 mg) and stirred for 24 h at 60 °C. After the 
removal of most of the DMF under high vacuum, the remaining product was taken up in 
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30% aqueous sodium acetate. This was followed by precipitation of the sodium salt using 
~10 volumes of cold ethanol. The precipitated product was further purified using 
Millipore filter (NMWC 3-30 kDa) at 4000 g. 
 
2.3.5 Structural characterization 
2.3.5.1 Determination of molecular weight of sulfated and unsulfated DHP fractions  
The number and weight average molecular weight of unsulfated DHP fractions was 
measured using gel permeation chromatography (GPC). Size exclusion chromatography 
(SEC) was employed in case of sulfated DHP fractions for determination of peak average 
molecular weight.  In both cases the system was composed of LC10Ai pumps and a SPD-
10A VP UV-vis detector controlled by a SCL-10A VP system controller connected to a 
computer. For SEC each fraction was analyzed using Asahipak GS320 HQ column with 
an isocratic flow rate of 0.7 mL/min of 0.1 N NaOH at pH 11.0. Polystyrene sulfonate 
standards (PSS) were used for calibration purposes. For GPC each fraction was analyzed 
using Phenogel 5 μ (Phenomenex, Torrance, CA, 7.6 mm i.d. x 300 mm). The mobile 
phase consisted of 100% tetrahydrofuran at a constant flow rate of 0.7 mL/min. 
Polystyrene standards (PS) were used for calibration purposes.   The relationship between 
logarithm of the molecular weight and the elution volume (V) of the standards was found 
to be linear with a correlation coefficient of 0.98 and 0.99. The wavelength of detection 
for CD and FD fractions was set at 280 nm. Each chromatogram was sliced into 1000 
time periods providing 1000 MR with the corresponding absorbance (A) values. These 
values were used to calculate number average molecular weight (MN), weight average 
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…… (1) …… (2) 
…… (3) 
MN = 
∑ Ai × Mi
∑ Ai
P = 
MW
MN
MW = 
∑ Ai × Mi
2
∑ Ai × Mi 
molecular weight (MW) and polydispersity (P) parameters from equations 1, 2, and 3, 
respectively, for each fraction.      
 
 
 
 
 
 
2.3.5.2 Elemental analysis 
Elemental Analysis of DHP samples was obtained from Atlantic Microlabs (Norcross, 
GA). 
 
2.3.5.3 NMR 
1
H- and 
13
C- NMR spectra were recorded with a Bruker AVANCE II 400 FT-NMR (400 
MHz) spectrometer in water-d and DMSO-d for sulfated and unsulfated fractions with 
tetramethylsilane (TMS) as an internal standard. Chemical shifts (δ) are reported in δ-
values (ppm). 
 
2.3.6 Prothrombin time and activated partial thromboplastin time  
Clotting time was determined in a standard 1-stage recalcification assay with a BBL 
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD). For PT and APTT assays, the 
reagents were pre-warmed to 37 °C. For PT assays, 10 μL of the anticoagulant (or the 
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Y =  YO +
YM − YO
1 + 10(log[L]O − log IC50) × HC
…... (4) 
reference molecule) was mixed with 90 μL of citrated human plasma, incubated for 30 s 
at 37 °C quickly followed by addition of 200 μL pre-warmed thromboplastin. For APTT 
assays, 10 μL of the anticoagulant was mixed with 90 μL citrated human plasma and 100 
μL 0.2% ellagic acid. After incubation for 240 s, clotting was initiated by quickly adding 
100 μL of 25 mM CaCl2. Each experiment was performed in duplicate. The averaged 
data was fitted using a quadratic equation to calculate the concentration of the 
anticoagulant necessary to double the clotting time (2 × PT or 2 × APTT). 
 
2.3.7 Proteinase inhibition 
Direct inhibition of thrombin and fXa by sulfated and unsulfated DHP fractions was 
determined through a chromogenic substrate hydrolysis assay. For these assays, a 10 μL 
DHP fraction at several different concentrations was diluted with appropriate buffer 
system in a PEG 20,000 coated polystyrene cuvettes. This was followed by addition of 
the 5µL of proteinase, thrombin (960nM) or fXa (1µM) and incubated at 37°C for 10 
minutes. Following incubation, 10µL of spectrozyme TH (2mM) or spectrozyme fXa 
(5mM) was rapidly added and the residual thrombin activity was quantified by measuring 
the initial rate of hydrolysis from the linear increase in absorbance at 405 nm as a 
function of time under conditions wherein less than 10% substrate is consumed. Relative 
residual proteinase activity at each activity measured under otherwise identical 
conditions, except for the absence of the inhibitor. Logistic equation 4 was used to fit the 
dose dependence of residual proteinase activity to obtain IC50. 
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In this equation Y is the ratio of residual thrombin activity in the presence of the inhibitor 
to that in its absence; YM and Y0 are the maximum and minimum possible values of the 
fractional residual thrombin activity, respectively; IC50 is the concentration of the 
inhibitor that results in 50% inhibition of enzyme activity, and HS is the Hill slope. HS 
does not represent co-operativity because the sulfated and unsulfated DHP fractions are a 
highly complex species that may possess multiple binding modes and geometries. 
Sigmaplot 9.0 (SPSS, Inc. Chicago, IL) was used to perform non-linear curve fitting in 
which YM, YO, IC50 and HS were allowed to float.  
 
2.3.8 Mechanistic studies 
2.3.8.1 Michaelis-Menten kinetics 
Several concentrations of Spectrozyme TH (0.25 to 25 μM) were treated with 4 nM 
thrombin in presence of fixed concentration of inhibitor (0 - 5 μg/mL). The initial rate of 
substrate hydrolysis was monitored from the linear increase in A405 in 20 mM Tris-HCl 
buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 at 25 °C. 
The data obtained was fitted by the standard Michaelis-Menten equation to calculate that 
apparent KM and VMAX. 
 
2.3.8.2 Competitive binding studies with exosite ligands [5F]-Hir[54-65](SO3-) or 
porcine heparin 
Inhibitor-dependent thrombin inhibition studies in the presence of [5F]-Hir[54-65](SO3-) 
or porcine heparin were performed in a manner similar to that described above using the 
chromogenic substrate hydrolysis assay. Briefly, a solution of inhibitor over several 
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different concentrations and thrombin (4nM) was incubated for 10 minutes at 37°C with 
either [5F]-Hir[54-65](SO3-) (0 and 86 nM) or porcine heparin (0, 20 and 100 M) in 20 mM 
Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000. 
Following incubation, Spectrozyme TH was added to yield a final concentration of 20µM 
and its hydrolysis was measured as the initial change in absorbance at 405. The molecular 
weight of bovine heparin was assumed to be 15000, as reported in the literature. The 
dose-dependence of the fractional residual proteinase activity at each concentration of the 
competitor was fitted by equation 04 to obtain the apparent concentration of inhibitor 
required to reduce thrombin activity to 50% of its initial value (IC50,app). 
 
2.3.9 Cellular toxicity studies 
The alamar blue assay was performed with a fluorimetric method using HepG cells in a 
96-well plate. The wells contained 100 µL of medium containing cells to which 10 µL of 
alamar blue was added and incubated for 4 hours at 37°C. The plates were exposed to an 
excitation wavelength of 531 nm and the emission at 590 nm was recorded on a Perkin 
Elmer fluorimeter. The percent viability was expressed as fluorescence emitted by treated 
cells compared to control (medium or vehicle only).      
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2.4 Results 
2.4.1 Synthesis of unsulfated and sulfated DHPs and its fractions 
Based on our earlier reports from our work we know that sulfated DHPs of CA (CDS) 
and FA (FDS) were potent dual inhibitors of thrombin and fXa. Both are a heterogeneous 
and complex mixture of molecules containing variety of chain lengths and linkages 
posing a hindrance in identification of the effector molecule. To identify the optimum 
chain length, which can be further optimized we decided to synthesize them on large 
scale. Both CD and FD were synthesized from their respective starting monomers using 
oxidative coupling reaction using an enzyme, HRP (figure 14).  This reaction generates 
free radical intermediates, which reacts with monomers to form a coupled product. This 
reaction persists until stopped to form longer oligomers and possibly variable linkages at 
the point of attachment. β-O-4 and β-5 type of linkages are easily feasible with this type 
of reaction as also seen in natural lignins which contain high amount of these linkage-
types in addition to others.  
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A part of these DHP samples synthesized enzymatically were subjected to different size 
MWCO filters (30kDa to 3kDa) where they were fractionated based on their molecular 
size (figure 15). In all, five samples of each DHP were obtained from this exercise. The 
samples that passed through the MWCO filter 3kDa were discarded as it would contain 
high amount of salt and unreacted starting material, if any.  
Figure 14. Chemo-enzymatic synthesis of 4-hydroxycinnamic acid-based dehydropolymers 
(DHPs), CD and FD.  
Horseradish peroxidase (HRP)-catalyzed oxidative coupling of caffeic acid (CA) or ferulic acid 
(FA) in the presence of H2O2 generates oligomers of size 3–34 U. Phenolic oxidation generating 
radical intermediates I1 and I2 couple with starting material to give oligomers with different types 
of inter-monomeric linkages. The most common linkages formed include β-O-4 and β-5.124 
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DHP mixture
 
 
 
 
 
 
 
Further 50mg of all 10 samples were subjected to sulfation to yield the sulfated counter 
part of each DHP. DHPs were sulfated using TEAST complex under conditions 
established earlier in our lab and a brief description can be found in the methods section. 
In this reaction the free hydroxyl and the free phenolic groups are sulfated (figure 16). 
Introduction of sulfate groups impart a greater anionic character to the DHPs.  
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Fractionation of CD and FD using MWCO filters ranging from 30 – 3 kDa 
Figure 16. Sulfation of CD and FD using triethylamine sulfur-trioxide complex  
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2.4.2 Molecular weight and size determination 
To determine molecular weight of the sulfated and unsulfated DHPs and its fraction SEC 
and GPC respectively were employed. PS and PSS standards were used for GPC and 
SEC methods respectively (figure 17). In both cases DHPs of FA were found to be larger 
in size, generating longer chains. The peak average molecular weight (MP) of unsulfated 
CD fractions ranged from 900 to 2210 while for FD fractions it was found to be 750 to 
7700. The MP of sulfated CD fractions ranged form 950 to 2890 while for sulfated FD 
fractions it was less than 1550 to 9780. Chain lengths were calculated by dividing the MP 
by the molecular weight of the starting monomer, which was in turn back calculated from 
the standard curve, obtained using PS. The molecular weight of the CA and FA were 
determined to be 262 and 226 respectively. The average peak chain length for CD 
fractions using PS standards ranged from 3.4 to 8.4 whereas, for FD oligomers it was 
found to range from 3.3 to 24.0 (Table 01). This implies the wider chain distribution 
pattern for FD fractions (7.3-fold) and CA (2.5-fold). The apparent molecular weight 
calculated for sulfated fractions using SEC were found to be the lowest for 3CDS (950) 
and highest for 30FDS (9780). Further, the difference in the molecular weights of the 
sulfated and the unsulfated DHPs obtained by SEC and GPC gives an apparent molecular 
weight of the total number of sulfates that might be present. Using the difference and 
dividing it by the chain length we can calculate the apparent number sulfates groups on 
DHPs (Table 02). The apparent average number of sulfates for all CD fractions was 
determined to be 3 sulfates per dimer with the exception of 3CD having 0.2 sulfate per 
monomer. A similar calculation for FD fractions revealed an average of 1 sulfate per 
dimer for all fractions. The average number of sulfates for the parent mixture of DHPs of 
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both CA and FA were 1 and 0.5 sulfate per monomer. Overall, this indicates that CD 
fractions are smaller in size (~3-fold) and more sulfated (2-3-fold) than the FD fractions, 
overall imparting a more anionic character to them. The MN values for the unsulfated CD 
and FD fractions ranged from 1052 to 7558, while MW was found to be in the range of 
2084 and 16464. This when compared with MP values indicate the presence of greater 
number of smaller chains in the mixture. Refer Table 01 below for all the molecular 
weight characteristics for each fraction of the unsulfated DHPs and their chain lengths. 
 
 
Table 01: Molecualr weight characterization of CD and FD fractions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
Number, weight, and peak average molecular weights were obtained by GPC analysis. 
b
Polydispersity. 
c
The peak average chain length was calculated from the ratio of MP and 
molecular weight of the two monomers calculated using PS standard curve. Numbers in brackets 
refer to the range of chain lengths (see Experimental Methods). 
 
MNa MWa MPa Pb LRc
(Da) (Da) (Da)
FD3 1270 5299 750 4.2 3.3 (1-25)c
FD5 2750 9690 1300 3.5 5.7 (1-44)
FD10 4997 13209 2650 2.6 11.7 (1-58)
FD30 7558 16464 7700 2.2 34.0 (1-72)
FDMIX 5322 11525 5440 2.2 24.0 (1-49)
CD3 1052 2084 900 2.0 3.4 (1-9)
CD5 1629 6927 1100 4.3 4.2 (1-28)
CD10 2484 8588 1470 3.5 5.6 (1-46)
CD30 3937 12788 1980 3.2 7.6 (1-50)
CDMIX 4264 13272 2210 3.1 8.4 (1-51)
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Table 02
: a
Peak average molecular weights obtained by GPC analysis (see Experimental 
Methods).  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
MP S MP US MP (S-US) ST LR S/unit
(Da) (Da) (Da)
FA 226.4a
CA 262.1a
03FD 750 3.3
05FD 1550 1300 250 3.1 5.7 0.54
10FD 3170 2650 520 6.5 11.7 0.56
30FD 9780 7700 2080 26.0 34.0 0.76
FD 6350 5440 910 11.4 24.0 0.47
03CD 950 900 50 0.6 3.4 0.18
05CD 1690 1100 590 7.4 4.2 1.76
10CD 2200 1470 730 9.1 5.6 1.63
30CD 2880 1980 900 11.3 7.6 1.49
CD 2890 2210 680 8.5 8.4 1.01
MP S refers to peak average molecular weight of sulfated fractions obtained by SEC analysis. 
MP US refers to peak average molecular weight of unsulfated fractions obtained by GPC analysis. 
MP (S-US) refers to peak average molecular weight of sulfate(s) obtained by subtracting 
unsulfated fractions from the sulfated ones. 
ST refers to total number of sulfates present obtained by dividing peak average molecular weight 
of sulfate(s) by calculated molecular weight of sulfate. 
LR refers to peak average chain length calculated from the ratio of MP and molecular weight of the 
two monomers calculated using PS standard curve.   
S/unit refers to apparent number of sulfates calculated from the ratio of total number of sulfates 
(ST) and peak average chain length (LR). 
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Figure 17. GPC and SEC of CD and FD fractions using PS and PSS as standards, 
respectively.    
A) & B) represent the linear curve obtained using PS (using GPC) and PSS (using SEC), 
respectively. A1) & A2) are the chromatograms acquired using GPC for CD and FD fractions, 
respectively. A2) and B2) are the chromatograms acquired using SEC for CDS and FDS fractions, 
respectively. 
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C (%) H (%) O (%) S (%) S/unit
30CDS 44.9 (51.1)a 3.1 (3.7) 37.1 (39.1) 5.8 (5.7) 0.38
30FDS 52.7 (56.1) 4.4 (4.4) 34.7 (36.3) 3.2 (3.2) 0.20
10CDS 46.1 (52.3) 3.5 (3.7) 35.6 (38.7) 5.1 (5.2) 0.33
10FDS 48.4 (57.0) 4.4 (4.4) 36.4 (35.9) 3.0 (2.7) 0.16
05CDS 49.0 (54.1) 3.2 (3.9) 35.0 (38.0) 3.6 (4.0) 0.25
2.4.3 Elemental analysis 
To assess the level of sulfation elemental analysis was carried out to determine the 
composition of each element. Average chain length determined by GPC was used to 
calculate the theoretical number of sulfates for all samples. The number of sulfates for 
CDS30, CDS10, FDS30 and FDS10 using elemental analysis were found to be 0.38, 
0.33, 0.2 and 0.16 per monomer which were fairly similar compared to the theoretical 
numbers (Table 03). The difference arises due to the heterogeneous nature of the samples 
making it extremely difficult to assign an exact size or composition. There is a ~2-fold 
difference in the level of sulfation between each group, CDS30-FDS30 and CDS10-
FDS10.  
 
 
Table 03: Elemental Analysis of sulfated fractions of DHP
  
 
 
 
 
 
 
 
 
 
 
 
a
Number in brackets show the predicted composition of a homogenous β-O-4-linked oligomer of 
appropriate sulfated DHP fraction. The peak average chain length was used in these calculations 
are represented in Table 02.    
S/unit refers to average number of sulfates per monomeric unit, which was calculated from 
elemental sulfur composition and the size of an average unsulfated oligomer. 
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A) 
B) 
2.4.4 NMR 
The 
1
H NMR spectra of parent DHPs showed the presence of broad peaks (not shown), 
which on fractionation to lower molecular weight did not resolve enough for structural 
assignments (figure 18A) indicative of a polydisperse nature. The quantitative 
13
C NMR 
like the 
1
H was only indicative of the functional group type present in the DHP mixture 
(figure 18B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. A) 
1
H NMR spectra of FD and B) quantitative 
13
C NMR spectra of CD both in 
DMSO-d6. 
Four regions are apparent in both the spectra, the carboxylic acid region between 10-11ppm in 
1
H 
or 160-170 ppm in 
13
C, the aromatic and vinylic peaks between 6-8ppm in 
1
H or 100-160 ppm in 
13
C, the α and β-carbons of alkoxy groups between 5-5.2 ppm in 1H or 70-80 ppm in 13C, and the 
methoxyl groups at 3.8ppm in 
1
H or 56 ppm in 
13
C. Solvent signal is observed at 2.5 ppm in 
1
H or 
40 ppm in 
13
C. 
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2.4.5 Plasma clotting assays  
Prothrombin and activated partial thromboplastin time (PT and APTT) are reflective of 
the activity of the extrinsic and intrinsic pathways of coagulation. Both are commonly 
used to assess the coagulation status of human plasma. APTT and PT were measured in 
duplicate or triplicate over a range 10-12 different concentrations of sulfated and 
unsulfated DHP fractions. Water was used as blank and enoxaparin was used as a 
reference indicator. All fractions exhibited a significant concentration-dependent 
prolongation of PT and APTT. The anticoagulant activity is a measure of the amount of 
anticoagulant required to double the clotting time (2 x APTT or 2 x PT). The amount of 
sulfated and unsulfated CD fractions required to achieve the doubling of plasma clotting 
time ranged from 18 (6.3 µM) to 200 µg/mL (222.2 µM) and 51 (17.7 µM) to 682 µg/mL 
(757.8 µM) for APTT and PT respectively (figure 19a & b). Likewise, concentrations 
ranging from 30 to 203 µg/mL (3.0 to 270.7 µM) and 74 to 248 µg/mL (7.6 to 597.3 µM) 
of sulfated and unsulfated FD fractions were required in the APTT and PT assays 
respectively (figure 19c & d), refer Table 04. This indicated that our samples were more 
potent anticoagulant (1.8-3.4-fold) in acting through the intrinsic pathway. In contrast, 
enoxaparin brought about 2 x APTT at 5.4 µg/mL (1.2 µM) and 2 x PT at 338.9 µg/mL 
(75.3 µM). This imply that our samples were at least 2.5-fold weaker in the APTT assay 
and at most 9.9-fold more potent in the PT assay. Also, there is a clear trend with the 
longer chains in both CD and FD being more potent than the smaller ones. When sulfate 
and unsulfated CD and FD fractions are compared side by side there is no significant 
difference except for 30CDS and 30CD being 3.6 and 2.1-fold more active, which is still 
not enormous. 
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Figure 19: Plasma clotting assay for both unsulfated and sulfated CD and FD fractions 
a) & b) figures represent APTT and PT results for CD and CDS fractions 
c) & d) figures represent APTT and PT results for FD and FDS fractions 
c) 
d) 
a) b) 
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2.4.6 Direct Inhibition of Coagulation Proteinases 
It is evident by the APTT and PT assays that all DHP fractions are able to double the 
plasma clotting time. This signifies that most likely it is acting through the common 
pathway in the coagulation cascade. The two key proteinases in the common pathway 
being thrombin and fXa we chose to investigate if our DHP fractions indeed affect their 
proteolytic activities. Enzyme inhibition studies were performed where the substrate 
PT and APTT values were deduced in in vitro human plasma experiments where the clot initiator 
is either thromboplastin or ellagic acid,respectively. Experiments were performed in duplicate or 
triplicate. Errors represent ±1 SE. 
nd – Not determined 
 
APTT PT
(μg/ml) (μM) (μg/ml) (μM)
CDS 23 ± 1.8 8 ± 0.6 63 ± 5.0 21.8 ± 1.7
CD 36 ± 1.8 16.3 ± 0.8 125 ± 6.3 56.6 ± 2.8
30CDS 18 ± 1.3 6.3 ± 0.4 51 ± 3.6 17.7 ± 1.2
30CD 49 ± 1.5 24.8 ± 0.7 119 ± 3.6 60.1 ± 1.8
10CDS 57 ± 1.1 25.9 ± 0.5 166 ± 3.3 75.5 ± 1.5
10CD 72 ± 3.6 49 ± 2.5 191 ± 9.6 129.9 ± 6.5
05CDS 109 ± 3.3 64.5 ± 1.9 272 ± 8.2 161 ± 4.8
05CD 130 ± 7.8 118.2 ± 7.1 385 ± 23.1 350 ± 21
03CDS 160 ± 16 168.4 ± 16.8 542 ± 54.2 570.5 ± 57.0
03CD 200 ± 16 222.2 ± 17.8 682 ± 54.6 757.8 ± 60.6
FDS 36 ± 1.1 5.7 ± 0.2 98 ± 2.9 15.4 ± 0.5
FD 66 ± 1.3 12.1 ± 0.2 182 ± 3.6 33.5 ± 0.7
30FDS 29.5 ± 1.2 3.0 ± 0.1 74 ± 3.0 7.6 ± 0.3
30FD 53 ± 3.2 6.9 ± 0.4 132 ± 7.9 17.1 ± 1.0
10FDS 72 ± 3.6 22.7 ± 1.1 198 ± 9.9 62.5 ± 3.1
10FD 99 ± 4.0 37.4 ± 1.5 287 ± 11.5 108.3 ± 4.3
05FDS 144 ± 10.1 92.9 ± 6.5 265 ± 18.6 171 ± 12.0
05FD 165 ± 13.2 126.9 ± 10.2 290 ± 23.2 223.1 ± 17.9
03FDS nd nd nd nd
03FD 203 ± 22.3 270.7 ± 29.7 448 ± 49.3 597.3 ± 65.7
Table 04: Anticoagulation effect of DHP fractions on plasma 
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hydrolysis was measured in presence of a range of inhibitor concentrations. The substrate 
hydrolysis decreased in sigmoidal fashion with the increase in concentration of the 
inhibitors. A standard dose-dependent equation was used to fit the curve and derive IC50 
values.     
 
The unsulfated and sulfated DHP fraction showed dual inhibition by inhibiting both 
thrombin and fXa. The IC50 values of unsulfated FD and CD fractions were found to be 
from 855 to 8610 ng/mL (0.111-11.5 µM) and 231 to 3360 ng/mL (0.117-3.7 µM) in case 
of thrombin (figure 20 a-b), whereas for fXa it ranged from 1730 to 11143 ng/mL 
(0.225-14.9 µM) and 263 to 8240 ng/mL (0.133-9.2 µM) respectively (figure 20 c-d). 
Likewise, IC50 values of sulfated FD and CD fractions vary 508 to 2320 ng/mL (0.052-
1.5 µM) and 91.6 to 2840 ng/mL (0.032-2.9 µM) for thrombin (figure 20 a-b); similarly 
for fXa inhibition the values were 1090 to 4990 ng/mL (0.112-3.2 µM) and 132 to 3750 
ng/mL (0.046-3.9 µM) (figure 20 c-d). See Table 05 and 06 for inhibition related data of 
all fractions. This suggests few notable features of our fractionated DHPs. First, the 
inhibition pattern for both the proteases clearly shows chain length dependence; where 
longer chains are more active most probably due to better interactions with the large 
binding sites on thrombin and fXa. Secondly, in concurrence with the parent DHP 
mixture the fraction as expected inhibit thrombin better than fXa (up to 2.9-fold weaker). 
Lastly, the most striking observation is the difference in inhibition between the sulfated 
and unsulfated species. The sulfated DHP fractions are better inhibitors of both the 
proteases as compared to its unsulfated counterpart (up to 3.7-fold). This is not a huge 
difference considering the fact that these samples are being used for development of 
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better drugs through structure-based drug design. Lastly, the unsulfated possess less 
anionic character making it better suitable for further development as it reduces the 
possibility of untoward interactions with the blood coagulation proteases.   
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Figure 20. Inhibition of blood coagulation proteases, thrombin (a&b) and fXa (c&d) by sulfated 
and unsulfated DHP fractions  
a) & b) represent the sigmoidal inhibition profile of thrombin by sulfated and unsulfated CD and FD 
fractions 
c) & d) represent the sigmoidal inhibition profile of fXa by sulfated and unsulfated CD and FD fractions 
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log IC50 
(mg/ml) 
YO YM HS IC50 (μg/ml) IC50 (nM)
CDS -3.97 ± 0.04 21.4 ± 1.7 103 ± 2.0 1.0 ± 0.1 0.108 ± 0.01 37.4 ± 3.5
CD -3.59 ± 0.03 20.8 ± 1.4 102 ± 1.8 1.0 ± 0.1 0.258 ± 0.02 116.7 ± 9.1
30CDS -4.04 ± 0.05 21.6 ± 2.0 104 ± 2.6 1.0 ± 0.1 0.092 ± 0.01 31.8 ± 3.5
30CD -3.64 ± 0.03 22.1 ± 1.3 101 ± 1.5 1.1 ± 0.1 0.231 ± 0.02 116.7 ± 5.1
10CDS -3.79 ± 0.04 28.3 ± 1.8 103 ± 1.7 1.3 ± 0.1 0.163 ± 0.01 74.1 ± 5.0
10CD -3.41 ± 0.02 24.0 ± 0.8 100 ± 0.7 1.3 ± 0.1 0.391 ± 0.01 266.0 ± 7.0
05CDS -3.38 ± 0.03 20.3 ± 1.7 100 ± 1.5 1.1 ± 0.1 0.420 ± 0.03 248.5 ± 18.0
05CD -3.25 ± 0.03 25.9 ± 1.8 103 ± 1.4 1.5 ± 0.1 0.568 ± 0.04 516.4 ± 36.0
03CDS -2.55 ± 0.04 21.8 ± 2.1 105 ± 2.5 1.1 ± 0.1 2.840 ± 0.28 2989 ± 295
03CD -2.47 ± 0.07 21.4 ± 3.9 106 ± 3.5 1.0 ± 0.2 3.360 ± 0.50 3733 ± 555
FDS -2.98 ± 0.05 17.6 ± 2.3 102 ± 1.1 0.7 ± 0.1 1.050 ± 0.11 92.6 ± 9.0
FD -2.69 ± 0.01 22.4 ± 0.5 101 ± 0.8 1.6 ± 0.1 2.060 ± 0.06 264.7 ± 20.2
30FDS -3.29 ± 0.03 26.5 ± 1.3 101 ± 1.4 1.3 ± 0.1 0.508 ± 0.03 51.9 ± 3.1
30FD -3.07 ± 0.03 21.8 ± 1.4 103 ± 1.9 1.0 ± 0.1 0.855 ± 0.06 111.0 ± 7.8
10FDS -2.94 ± 0.04 19.2 ± 2.4 102 ± 1.4 0.9 ± 0.1 1.150 ± 0.10 362.8 ± 31.5
10FD -2.70 ± 0.01 23.2 ± 0.5 102 ± 0.8 1.2 ± 0.1 2.020 ± 0.06 762.3 ± 22.6
05FDS -2.64 ± 0.05 21.5 ± 1.9 101 ± 2.7 1.0 ± 0.1 2.320 ± 0.02 1497 ± 12.9
05FD -2.50 ± 0.03 26.4 ± 1.3 101 ± 1.5 1.3 ± 0.1 3.160 ± 0.20 2431 ± 154
03FDS nd nd nd nd nd nd
03FD -2.07 ± 0.05 28.8 ± 4.3 103 ± 1.9 1.5 ± 0.2 8.610 ± 0.90 11480 ± 1200
Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM 
NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvettes. 
Spectrozyme TH was used as substrate and the residual enzyme activity in the presence of 
inhibitor was assessed by measuring the initial rate of substrate hydrolysis at 405 nm. Logistic 
equation 4 was used to fit the dose dependence of the residual enzyme activity to obtain log 
IC50, Y0, YM and HS values. See Methods for details. 
Errors represent ±1 SE 
Table 05: Inihibition of thrombin by sulfated and unsulfated DHP fractions 
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Table 06: Inihibition of fXa by sulfated and unsulfated DHP fractions 
 
log IC50 
(mg/ml) 
YO YM HS IC50 (μg/ml) IC50 (nM)
CDS -3.77 ± 0.06 1.66 ± 4.4 110 ± 3.6 0.6 ± 0.1 0.171 ± 0.02 59.2 ± 6.9
CD -3.43 ± 0.03 12.2 ± 1.9 105 ± 1.8 0.8 ± 0.1 0.368 ± 0.03 166.5 ± 9.1
30CDS -3.88 ± 0.05 21.5 ± 2.6 105 ± 2.7 1.0 ± 0.1 0.132 ± 0.02 45.8± 3.5
30CD -3.58 ± 0.09 16.5 ± 4.9 112 ± 6.3 0.7 ± 0.1 0.263 ± 0.05 132.8 ± 5.1
10CDS -3.41 ± 0.06 17.4 ± 3.8 99 ± 1.9 1.0 ± 0.1 0.390 ± 0.05 177.3 ± 5.0
10CD -3.10 ± 0.08 17.7 ± 5.3 102 ± 2.7 0.9 ± 0.1 0.804 ± 0.14 546.9 ± 7.0
05CDS -2.95 ± 0.06 19.2 ± 3.5 99 ± 2.1 1.1 ± 0.2 1.110 ± 0.14 650.9 ± 18.0
05CD -2.78 ± 0.04 14.0 ± 2.1 100 ± 1.3 1.0 ± 0.1 1.650 ± 0.14 1500 ± 36.0
03CDS -2.43± 0.20 15.4 ± 1.3 105 ± 3.4 0.6 ± 0.1 3.750 ± 1.69 3947 ± 1800
03CD -2.08 ± 0.02 18.0 ± 0.9 103 ± 1.0 1.1 ± 0.1 8.240 ± 0.39 9156 ± 433
FDS -3.23 ± 0.02 30.9 ± 0.8 101 ± 0.8 1.7 ± 0.1 0.588 ± 0.06 164.9 ± 9.0
FD -2.84 ± 0.03 22.9 ± 1.4 102 ± 1.7 1.1 ± 0.1 1.440 ± 0.11 377.9 ± 20.2
30FDS -2.96 ± 0.06 22.4 ± 3.6 102 ± 2.2 0.9 ± 0.1 1.090 ± 0.15 111.5 ± 3.1
30FD -2.76 ± 0.02 22.0 ± 1.1 100 ± 1.0 1.2 ± 0.1 1.730 ± 0.09 224.7 ± 7.8
10FDS -2.62 ± 0.03 11.6 ± 1.9 102 ± 1.3 0.8 ± 0.1 2.380 ± 0.18 750.8 ± 31.5
10FD -2.53 ± 0.04 18.2 ± 2.1 104 ± 2.5 1.0 ± 0.1 2.960 ± 0.28 1117 ± 22.6
05FDS -2.30 ± 0.02 24.1 ± 0.8 102 ± 1.0 1.1 ± 0.1 4.990 ± 0.24 3219 ± 12.9
05FD -2.19 ± 0.05 14.6 ± 3.8 105 ± 2.5 0.9 ± 0.1 6.530 ± 0.82 5023 ± 154
03FDS nd nd nd nd nd nd
03FD -1.95 ± 0.02 16.5 ± 0.9 103 ± 0.9 1.0 ± 0.1 11.10 ± 0.44 14857 ± 1200
Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM 
NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvettes. 
Spectrozyme fXa was used as substrate and the residual enzyme activity in the presence of 
inhibitor was assessed by measuring the initial rate of substrate hydrolysis at 405 nm. Logistic 
equation 4 was used to fit the dose dependence of the residual enzyme activity to obtain log 
IC50, Y0, YM and HS values. See Methods for details. 
Errors represent ±1 SE 
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2.4.7 Identifying the binding site of CD10 and FD10 
Based on the known mechanism of FDS and CDS mixtures we expected the fraction to 
behave the same way by acting through the exosite-2 on thrombin. We chose to work 
with an intermediate active fraction as the yields of the larger fractions were much higher 
after fractionation. This implies that the mixture possesses its activity mainly because of 
the larger fractions as evident by protease inhibition studies. To ascertain that indeed this 
was true we performed a quick study with one of the fractions from each and not 
surprisingly found the mechanism to be the same. Michaelis Menten kinetic studies with 
CD10 and FD10 were performed (figure 21a & b) to probe if the inhibitors were acting 
through binding at the active site. The KM was found to be steady between 1.2 – 1.8 µM 
and the VMAX steadily decreased from 24 – 11 mAbsU/min in presence of increasing 
concentration of the inhibitor (20 – 5000 ng/mL). The catalytic efficiency of the reaction 
steadily decreased from ~45 to ~18 s
-1
, refer Table 07. These signify that there is no 
effect on substrate binding to the active site to form the thrombin–Spectrozyme TH 
Michaelis complex but the conversion of the complex to the final product is definitely 
retarded. To further ascertain that the fractions like the parent DHPs bind in the exosite-2 
of thrombin, competitive binding studies in presence [5F]-Hir[54-65](SO3-), an exosite-1 
binding ligand (figure 22a & b) and heparin, an exosite-2 binding ligand (figure 23a & 
b) was performed. Based on previous studies we chose to screen exosite-1 ligand at a 
concentration of 86nM (3 x KD) and heparin at 20 µM (1 x KD) and 100 µM (5 x KD). 
These studies revealed that our fractions indeed bind in the exosite-2 of thrombin as 
IC50,app changed significantly from 210 nM to 946 nM and 600 nM to 7.3 µM for CD10 
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and FD10, respectively in presence of increasing concentration of exosite-2 competitor, 
whereas it remained unchanged in presence of exosite-1 competitor (Table 08).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21a & b: Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis by Thrombin in 
the presence of DHP fractions. 
Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by thrombin in the presence of 10CD 
(figure 20a) and 10FD (figure 20b). 
The initial rate of hydrolysis at various substrate concentrations was measured in pH 7.4 buffer as 
described in ‘Experimental Procedures’. Solid lines represent non-linear regressional fits 
to the  data using the Michaelis-Menten equation.
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Table 07: Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis by Thrombin in the 
presence of inhibitors   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[10CD]o Km Vmax kcat 
(ng/mL) (µM) (mAbsU/min) (s-1)
0 2.3 ± 0.1 27.0 ± 0.4 45.4 ± 0.7
20 1.4 ± 0.2 21.8 ± 0.7 36.6 ± 1.2
100 1.2 ± 0.1 18.8 ± 0.4 31.6 ± 0.7
400 1.2 ± 0.2 13.2 ± 0.3 22.2 ± 0.5
1000 1.8 ± 0.3 11.2 ± 0.4 18.8 ± 0.7
[10FD]o
0 2.3 ± 0.1 27.0 ± 0.4 45.4 ± 0.7
100 1.2 ± 0.2 23.8 ± 0.7 40.0 ± 1.2
500 1.4 ± 0.2 20.5 ± 0.5 34.4 ± 0.8
2000 1.3 ± 0.3 14.6 ± 0.7 24.5 ± 1.2
5000 1.3 ± 0.2 11.0 ± 0.3 18.5 ± 0.5
a
KM and VMAX were measured as described in ‘Experimental Procedures’. 
b
Error represents 1 S.E. 
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Figure 23. Inhibition of thrombin by DHP in presence of exosite-2 ligand 
Competitive effect of porcine heparin on the inhibition of thrombin by 10CD (figure 22a) and 
10FD (figure 22b). Residual thrombin activity was measured through Spectrozyme TH hydrolysis 
in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % 
polyethylene glycol (PEG) 8000 at 37 
O
C in the presence of 0, 20 and 100 μM porcine heparin. 
Solid lines represent fits using the logistic equation 4 to obtain the apparent IC50, as described in 
‘Experimental Procedures’. 
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Figure 22. Inhibition of thrombin by DHP in presence of exosite-1 ligand 
Competitive effect of [5F]-Hir[54-65](SO3
-
) on the inhibition of thrombin by 10CD (figure 21a) 
and 10FD (figure 21b). Residual thrombin activity was measured through Spectrozyme TH 
hydrolysis in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % 
polyethylene glycol (PEG) 8000 at 37 
O
C in the presence of 0 and 86 nM [5F]-Hir[54-65](SO3
-
). 
Solid lines represent fits using the logistic equation 4 to obtain the apparent IC50, as described in 
‘Experimental Procedures’. 
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Table 08: Inhibition of thrombin by 10CD and 10FD in the presence of hirugen analog [5F]-
Hir[54-65](SO3-) and porcine heparin
 a
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.8 Cellular toxicity studies 
The alamar blue assay functions on the ability of viable cells to reduce alamar blue 
(resazurin) to resofurin (highly red fluorescent), which can be quantified using 
fluorimeteric methods. All fractions screened for cytoxicity were found to be non-toxic 
with more than 80% cell viability at concentration as high as 500 µg/mL (figure 24).  
 
 
 
 
 
a
 Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 
2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvette. Spectrozyme TH 
was used as substrates and the residual enzyme activity in the presence of FDSO3 was assessed 
by measuring the initial rate of substrate hydrolysis at 405 nm. Logistic equation I was used to fit 
the dose dependence of the residual enzyme activity to obtain log IC50, Y0, YM and HS values. 
See Methods for details. 
b
 represents 1 ±S.E. 
[Competitor]
log IC50
(mg/ml)
Y0 YM HS IC50 (µg/ml) IC50 (nM)
Hirugen Analog
[10CD] 0nM -3.51 ± 0.3 25.8 ± 1.2 99.2 ± 1.2 1.4 ± 0.1 0.31 ± 0.02 211 ± 13.6
86nM -3.41 ± 0.02 20.4 ± 0.9 101 ± 0.8 1.5 ± 0.1 0.39 ± 0.01 265 ± 6.80
[10FD] 0nM -2.80 ±0.02 23.1 ± 0.6 102 ± 0.9 1.2 ± 0.1 1.59 ± 0.05 600 ± 18.9
86nM -2.70 ± 0.08 21.2 ± 3.5 106 ± 4.8 1.1 ± 0.2 1.98 ± 0.30 747 ± 113
Porcine Heparin
[10CD] 20μM -3.16 ± 0.02 27.5 ± 1.2 99.8 ± 1.0 1.5 ± 0.1 0.70 ± 0.04 476 ± 27.2
100μM -2.86 ± 0.02 36.7 ± 0.9 100 ± 0.4 1.0 ± 0.1 1.39 ± 0.06 945 ± 40.8
[10FD] 20μM -2.16 ± 0.06 21.0 ± 3.0 102 ± 2.1 0.8 ± 0.1 6.95 ± 0.90 2600 ± 340
100μM -1.72 ± 0.06 29.9 ± 2.7 101 ± 1.5 0.9 ± 0.1 19.3 ± 2.60 7300 ± 981
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2.5 Discussion 
In an attempt to mimic structural features of heparin by replacing the carbohydrate 
backbone with an aromatic scaffold and also contain structural intricacy similar to that of 
heparin we chose to work with lignins containing the carboxylate functionality. However, 
natural lignins do not contain carboxylic acid groups. So, what does lignin have to offer? 
It is a complex and heterogenous polymer just like heparin. It has a rigid aromatic 
backbone with flexibility introduced at the point of attachment of each monomer, a 
property lacked by heparin. The aromatic skeleton might impart structural specificity due 
to its hydrophobic nature and restrained conformation. Lignins contain diverse type of 
linkages and the molecular weight is close to 5000 a property shared with LMWH. 
Lignins have free –OH groups, which could potentially make H-bonding or could be 
derivatized to yield its sulfated form. In terms of synthesis these are easy to synthesize 
even on bulk scale, which is not the case with heparins. Finally, lignins offer an avenue to 
Figure 24. Toxicity studies on the unsulfated CD and FD fractions 
The alamar blue assay was performed with a fluorimetric method using HepG cells. All fractions 
of both CD and FD were able to sustain cell viability at concentrations as high as 500 μg/ml. 
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potentially discover sequence(s) similar to that of the potent pentasaccharide sequence in 
heparin.  
 
We utilized HRP-catalyzed oxidative coupling conditions, such as high reactant 
concentrations and controlled gradual addition of the oxidant, which reduce chain 
termination, to obtain oligomers with peak average molecular weight between 750-7700. 
This corresponds to a very diverse chain length numbers ranging from a trimer up to 24-
mer. The GPC profiles obtained were broad and reasonably symmetrical implying that 
each fraction contained nearly all types of chains. For example, although the average 
chain length of FD3 and CD3 is 3.4 and 3.3, both fractions contain chains as long as 24 
and 8 units, respectively. This indicates that each type of the chain length is present in all 
fractions but in different proportions giving rise to polydispersity. This is possible 
because some of the longer chains are conformationally more flexible facilitating their 
passage through the sieves of the filter. The apparent molecular weight of the sulfated 
fractions of DHPs was measured using SEC with PSS as standards.  
 
We have employed the use of chain lengths and difference in the number obtained 
between the sulfated and unsulfated fractions to get an insight into the apparent number 
sulfates present. The calculation for number of sulfate groups turns out to be 1-1.8 per 
monomer of CD and 0.5-0.8 sulfates per monomer of FD. Further, we attempted to obtain 
a correlation between sulfates group obtained by chromatography and elemental analysis. 
The number of sulfates for CDS30, CDS10, FDS30 and FDS10 using elemental analysis 
were found to be 0.38, 0.33, 0.2 and 0.16 per monomer. The level of sulfation determined 
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using both the techniques differ by 3-4-fold but the ratio between the sulfates remain the 
same. This can be attributed to two things; first, the highly heterogeneous nature of the 
samples and second the methods used to determine them. SEC measures the hydro-
dynamic volume of the sample, hence for similar size molecules the molecular weights, 
might be different if the conformations are different. One sample might carry more 
solvent molecules with it than the other increasing its overall size and hence the apparent 
molecular weight.  
 
Detailed structural characterization involving the exact type of inter-monomeric linkages 
is very challenging. The 
13
C-NMR just like the IR revert only functional group 
information on these complex samples. Due to lack of powerful mass spectroscopy 
techniques and expertise in polymer chemistry assigning linkages based on daughter ions 
for this intricate mixture is not very reliable. All the functionality of the starting 
monomer; hydroxyl, -carboxylic acid, aliphatic side chains, aromatic backbone and 
methoxy (in case of FA) are retained in oligomers as evident by NMR.  
 
Working with such a complex mixture would limit the discrete assignment of structures 
despite the availability of modern and powerful techniques like NMR, MS and XRD (X-
ray diffraction). This drawback is outweighed by the fact that the mixture presents an 
opportunity for high throughput screening of a large library, which would yield an 
effective structure(s) rather than a discrete one. In the case of carboxylated lignins it is 
combinatorial because of the nearly random coupling of radicals.  
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The anticoagulation properties of DHP fractions were tested using an in vitro assay to 
assess APTT and PT. The results reveal that all the fractions are able to prolong the 
plasma clotting time for both APTT and PT assays. In addition, all samples show greater 
potency prolonging the clotting time in the PT assay compared to enoxaparin, a marketed 
LMWH used in clinical settings. The sulfated and unsulfated CD and FD fractions were 
2.5 to 225- fold weaker in the APTT assay compared to enoxaprain, whereas in PT assay 
the change observed ranged from 0.1 to 10-fold based on the size of the oligomers 
(figure 25a & b). The fraction implies that some of the samples were more potent in 
prolonging the clotting time compared to enoxaparin. Overall, it is evident from this 
study that the activity is a size dependent phenomenon, where larger samples are more 
active than the smaller ones. In addition, the larger samples are better in executing the 
coagulation through the intrinsic pathway. It is possible that the significant hydrophobic 
character of DHPs induces binding to cells resulting in significant sequestering of active 
agent. It is likely that this non-specific binding will be reduced with homogeneous, 
synthetic small molecules. Interestingly, the difference between sulfated and unsulfated 
samples in prolonging the clotting time was not huge. Sulfated CD fractions were better 
than unsulfated CD fractions by 1.3-3.9-fold and in case of FD fractions the difference 
was not more than 2.3-fold (figure 26). This suggest that sulfation in not very critical as 
is the case with heparins, where it is the root cause of numerous side effects. Finally, 
since the samples work through both the coagulation cascade it lead us to predict that 
either the samples are inhibiting numerous coagulation factors in the cascade or it worked 
through the common pathway by either inhibiting thrombin and/or fXa, just like the 
parent sulfated DHPs reported by our lab. 
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Figure 25. Comparison of sulfated and unsulfated DHP fractions against enoxaparin 
When compared with DHP fractions, enoxaparin is more potent in APTT assay, while in case of 
PT assay only the higher fractions are more potent than enoxaparin.  
*For comparison purposes of DHP fractions in PT assay, the fold concentrations have been 
further enhanced by 10-fold. Hence, the actual value of enoxaparin, which is 1, shows up as 10. 
 
 
 
 
 
 
 
 
 
Figure 26. Comparison between sulfated and unsulfated DHP fractions in the APTT and PT  
assays. 
A) Comparison for APPT results and B) PT results 
 
 
In the light of our prediction we carried out direct enzyme inhibition studies on thrombin 
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enoxaparin. All our samples directly inhibited the hydrolysis of appropriate chromogenic 
substrate by thrombin and fXa, whereas enoxaparin is not a direct inhibitor of these 
proteases. The IC50 values for sulfated and unsulfated samples ranged from ten’s of 
nanomolar to micromolar; the difference between the most and least active being ~3800-
fold. As observed in the clotting assays the sulfated samples were more active than the 
unsulfated ones ranged from 1.2-3.7-fold based on the size of the sample (figure 27). 
And the difference within the unsulfated and sulfated group of samples ranged from 20 to 
80-fold with the larger samples being more active the smaller ones (figure 28). Overall, 
this study suggests that the unsulfated DHPs possess size-dependent direct inhibition of 
thrombin and fXa, which are mechanistically different from heparins that work through 
the indirect AT mediated inhibition. 
 
 
 
 
 
 
Figure 27. Comparison between sulfated and unsulfated DHP fractions for their potency in 
inhibiting thrombin and fXa. 
Fold concentration was calculated by taking ratio of IC50 of unsulfated:sulfated fractions, 
indicative of greater potency of sulfated fractions. 
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Figure 28. Size Dependent comparison of DHP fractions for their potency in inhibiting 
thrombin (A) and fXa (B). 
 
 
Note: Sulfated DHP mixtures have been screened for other factors in the coagulation 
cascade and were found not to inhibit any enzyme up to 3 mM concentration. Also, these 
have been tested in presence of AT and the activity is not affected by more than 2-fold 
suggesting that our samples are indeed inhibitors of thrombin and fXa. 
 
In-vitro toxicity studies show that our DHP samples are not toxic up to a concentration of 
500 µg/mL. All fractions show excellent cell viability at the highest concentration used 
with the worst one 30FD showing more than 80% cell viability.  
 
2.6 Conclusion 
Although the heterogeneous and polydisperse nature of these DHP oligomers are 
structurally difficult to characterize it presents us with a wealth of information that could 
be used for rational design of advanced molecules. The molecules present in the mixture 
have a common scaffold of lignin carboxylate. Unsulfated DHPs have a reduced overall 
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negativity, which would arise only from the carboxylates on each monomer. This 
reduction in the overall anionic character of DHPs could potentially overcome the 
numerous unwanted interactions the sulfated DHPs might make while interacting with 
the serine proteases, thrombin and fXa. In order to find a sequence like the heparin 
pentasaccharide our chain length dependence studies revealed that an octamer size might 
be just right to work with, which can be finely tuned to generate more potent molecules. 
The other plausible strategy might be to further reduce the size to that of a tetramer or a 
hexamer and have strategically located functional groups that interact with the residues in 
the proteinase binding site and bring about inhibition. The samples represented in here, in 
an attempt to mimic heparin have a complete different mechanism of action. Heparins are 
indirect inhibitors, whereas our samples are direct inhibitors of thrombin and fXa. 
 
On the whole, this entire exercise entails that it may be possible to design un-sulfated, 
synthetic molecules with an optimum size that would possess unique mechanism of 
action. A specific advantage expected of these un-sulfated homogeneous DHP-based 
structures is that absence of sulfate group would make the molecules orally bioavailable. 
This does not imply that our novel molecules will be clinically effective. Though in-vitro 
studies suggest that our samples are not toxic up to a concentration of 0.5 g/L, in-vivo 
toxicity studies will have to be performed to ascertain that these novel structures do not 
induce abnormal effects. An important point to note in this regard is that in-vivo 
enoxaparin does not prolong PT and APPT at concentrations sufficient to anticoagulate 
suggesting that in-vitro potency does not translate directly into in-vivo effectiveness. Yet, 
the results described here suggest that the novel structures of DHPs with optimum size 
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and strategically placed functional groups may lead to a new class of potent 
anticoagulants. 
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CHAPTER 03 
Novel and Specific Direct Thrombin Inhibitor 
 
3.1 Background 
Our earlier studies on DHPs had shown that it might be possible to design a potent 
anticoagulant that would possess an optimal size with some anionic character and 
hydrophobicity. In the same study we had postulated that our DHPs contain mainly two 
types of linkages β-O-4 and β-5. The chain length and the linkage types were the main 
reason for the tremendous heterogeneity and polydispersity introduced in the DHP 
samples. Also, our DHP samples were found to be dual inhibitors of thrombin and fXa. 
As described earlier, multienzyme targeting is the main drawback that leads to numerous 
side effects that heparin carries. Our goal was to reduce the non-specific interaction as 
much as possible. Heparin targets several enzymes in the coagulation cascade, which we 
were able to overcome with our DHPs restricting it to act only as a dual inhibitor. After 
studying the size dependency on enzyme inhibition the next logical step was to study the 
structural decency. To study the inhibition arising from structural specificity we 
synthesized DHPs with only β-O-4 type linkages, which will be referred as TK. The other 
notable modification in TK was the absence of carboxylate groups. As we believed that 
some anionic character was essential for the protease inhibition we derivatized the 
hydroxyl groups on TK to the sulfates, and this derivative is labeled as TKS. This chapter 
refers to the study of TKS as a specific inhibitor of thrombin and as a potential 
anticoagulant. 
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3.2 Experimental Methods 
3.2.1 Proteins, biological fluids and chemicals 
Human plasma proteinases, fVIIa, fIXa, fXa, fXIa and α-thrombin, were purchased from 
Haematologic Technologies (Essex Junction, VT). Stock solutions of proteins were 
prepared as follows: For fVIIa 25 mM HEPES buffer, pH 7.4, containing 100 mM NaCl 
and 5 mM CaCl2. For fIXa 100 mM HEPES buffer, pH 8, containing 100 mM NaCl and 
10 mM CaCl2. For fXa 20 mM Sodium phosphate buffer, pH 7.4, 0.1mM EDTA, 0.1% 
PEG 8000. For fXIa and thrombin 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM 
NaCl and 2.5 mM CaCl2, 0.1% PEG 8000. Chromogenic substrates used - Spectrozyme 
FVIIa (methanesulphonyl-D-cyclohexylalanyl-butyl-Argp-nitroanilide), Spectrozyme 
FIXa (D-Leu-Phe-Gly-Arg-pnitroanilide), Spectrozyme FXa (Methoxycarbonyl-
Dcyclohexylglycyl-Gyl-Arg-p-nitroanilide), Spectrozyme TH (H-Dhexahydrotyrosol-
Ala-Arg-p-nitroanilide). All substrates were purchased from American Diagnostica 
(Greenwich, CT). Competitive ligands used - Exosite 1 ligand Tyr63-sulfated hirudin-
(54-65) labeled with 5-(carboxy)fluorescein ([5F]-Hir[54-65](SO3-)). Exosite 2 ligand 
unfractionated porcine heparin (Sigma-Aldrich St. Louis, MO). Plasma and blood work –  
Pooled citrated human plasma for coagulation time assays (Valley Biomedical 
Winchester, VA). Activated partial thromboplastin time reagent containing ellagic acid 
(APTT-LS), thromboplastin-D and 25 mM CaCl2 (Fisher Diagnostics Middletown, VA) 
Fresh human whole blood (self donor not on any medication for 4 weeks before sample 
collection) was collected in tubes containing sodium citrate 3.2% (0.109M). LMWH (MR 
5,060 Da), TEAST complex (Sigma St. Louis, MO). Enoxaparin (MR 4,500 Da) (Aventis 
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Pharmaceuticals). All other chemicals were analytical reagent grade from either Sigma 
Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA) and used as obtained. 
 
3.2.2 Synthesis of TKS 
TK, a β-O-4 polymer was obtained from Takao Kishimoto and sulfated as described 
below. Figure 29 shows the 
13
C-NMR spectra of TK. Sulfation of TK was carried out 
using TEAST as described earlier. Briefly, TK was sulfated with TEAST complex. 
Briefly, dry TK powder (50 mg) was dissolved in dry DMF (15 mL) containing TEAST 
(200 mg) and stirred for 24 h at 60 °C. After the removal of most of the DMF in vacuo, 
the remaining product was taken up in 30% aqueous sodium acetate, the sodium salt 
precipitated using ~10 volume of cold ethanol. The precipitated product was further 
purified using dialysis membrane (MWCO 5K).  
 
Figure 29. 
13
C-NMR spectra of β-O-4 type artificial lignin polymer.126 
 
 
 
71 
 
…… (1) …… (2) 
…… (3) 
MN = 
∑ Ai × Mi
∑ Ai
P = 
MW
MN
MW = 
∑ Ai × Mi
2
∑ Ai × Mi 
3.2.3 Molecular weight determination of TKS using size exclusion 
 chromatography (SEC). 
The apparent number and weight average molecular weight of TKS was determined using 
SEC on a Shimadzu chromatography system composed of LC10Ai pumps and a SPD-
10A VP UV-Vis detector controlled by a SCL-10A VP system controller connected to a 
computer. TKS was eluted on an Asahipak GS320 HQ column with an isocratic flow rate 
of 0.7 mL/min of 0.1 N NaOH at pH 11.0. The wavelength of detection for fractions was 
set to 280 nm. Polystyrene sulfonate standards (PSS) were used for calibration purposes. 
The relationship between logarithm of the molecular weight and the elution volume (V) 
of the standards was found to be linear with a correlation co-efficient of 0.99. Each 
chromatogram was sliced into 1000 time periods providing 1000 MR with the 
corresponding absorbance (A) values. These values were used to calculate MN, MW and P 
parameters from equations 1, 2 and 3, respectively, for TKS. 
 
 
 
 
 
 
3.2.4 Direct TKS inhibition of coagulation proteinases.  
Direct inhibition of fVII, fIX, fXa, fXIa and thrombin by TKS was determined using 
chromogenic substrate hydrolysis assays at physiological temperature. For these assays, 
TKS having final concentrations ranging from 0.23 ng/mL to 230 μg/mL was used with 
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Y =  YO +
YM − YO
1 + 10(log[L]O − log IC50) × HC
…... (4) 
appropriate buffer system in PEG 20,000-coated polystyrene cuvettes. The proteinase 
solution was then added each time to yield final concentrations ranging from 1 to 10 nM 
of each enzyme. The experiment was carried out at physiological temperature with an 
incubation time of 10 minutes. Following incubation, appropriate amount of chromogenic 
substrate was rapidly added to yield a final concentration of 20 to 50µM.  The residual 
thrombin activity was quantified by measuring the initial rate of hydrolysis from the 
linear increase in absorbance at 405 nm as a function of time under conditions wherein 
less than 10% substrate is consumed. Relative residual proteinase activity at each activity 
measured under otherwise identical conditions, except for the absence of TKS. Logistic 
equation 4 was used to fit the dose dependence of residual proteinase activity to obtain 
IC50. 
 
 
 
 
In this equation Y is the ratio of residual thrombin activity in the presence of TKS to that 
in its absence; YM and Y0 are the maximum and minimum possible values of the 
fractional residual thrombin activity, respectively; IC50 is the concentration of TKS that 
results in 50% inhibition of enzyme activity, and HS is the Hill slope. HS does not 
represent co-operativity because TKS is a polydisperse species that may possess multiple 
binding modes and geometries. Sigmaplot 10.0 (SPSS, Inc. Chicago, IL) was used to 
perform non-linear curve fitting in which YM, YO, IC50 and HS were allowed to float.  
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3.2.5 Michaelis-Menten kinetics of substrate hydrolysis by thrombin in the 
 presence of TKS. 
Several concentrations of Spectrozyme TH (0.5 to 40 μM) were treated with by 4 nM 
thrombin in presence of fixed concentration of TKS (0 - 2.3 μg/mL). The initial rate of 
substrate hydrolysis was monitored from the linear increase in A405 in 20 mM Tris-HCl 
buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 at 25 °C. 
The data obtained was fitted by the standard Michaelis-Menten equation to calculate that 
apparent KM and VMAX. 
 
3.2.6 Competitive binding studies with exosite ligands  
TKS-dependent thrombin inhibition studies in the presence of [5F]-Hir[54-65](SO3-) or 
porcine heparin were performed in a manner similar to that described above using the 
chromogenic substrate hydrolysis assay. Briefly, a solution of TKS (0 - 23 µg/mL) and 
thrombin (4nM) was incubated for 10 minutes at 37°C with either [5F]-Hir[54-65](SO3-) (0 
– 86 nM) or porcine heparin (0 – 100 M) in 20 mM Tris-HCl buffer, pH 7.4, containing 100 
mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000. Following incubation, Spectrozyme TH was 
added to yield a final concentration of 20µM and its hydrolysis was measured as the 
initial change in absorbance at 405 measured. The molecular weight of bovine heparin 
was assumed to be 15000 Da, as reported in the literature. The dose-dependence of the 
fractional residual proteinase activity at each concentration of the competitor was fitted 
by equation 4 to obtain the apparent concentration of TKS required to reduce thrombin 
activity to 50% of its initial value (IC50,app). 
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3.2.7 Prothrombin time and Activated Partial Thromboplastin Time for plasma 
 clotting assays in presence of TKS 
Clotting time was determined in a standard 1-stage recalcification assay with a BBL 
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD). For PT and APTT assays, the 
reagents were pre-warmed to 37 °C. For PT assays, 10 μL the anticoagulant (or the 
reference molecule) was mixed with 90 μL of citrated human plasma, incubated for 30 s 
at 37 °C quickly followed by addition of 200 μL pre-warmed thromboplastin. For APTT 
assays, 10 μL of the anticoagulant was mixed with 90 μL citrated human plasma and 100 
μL 0.2% ellagic acid. After incubation for 240 s, clotting was initiated by quickly adding 
100 μL of 25 mM CaCl2. Each experiment was performed in duplicate. The averaged 
data was fitted by a quadratic equation to calculate the concentration of the anticoagulant 
necessary to double the clotting time (2 × PT or 2 × APTT). 
 
3.2.8 Thromboelastograph (TEG
®
) Analysis of Clot Formation in the Presence of 
 TKS 
The assays were performed using Thromboelastograph® Coagulation Analyzer 5000 
(TEG
®
) (Haemoscope Corporation Niles, IL). Typically, these assays are performed to 
analyze the rate and structure of a clotting sample and its breakdown. Briefly, in the 
assays 20 μL of 200 mM CaCl2 was transferred into the Haemoscope
TM 
disposable cup, 
oscillating through 4°45’ angle at 0.1 Hz. This was followed by the addition of a mixture 
of 340 μL of sodium citrated whole blood containing 10 μL the anticoagulant or saline 
(control) at 37 °C. This recalcification initiates clot formation in the TEG
® 
coagulation 
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analyzer, which operates until all necessary data collection (R, K, α and MA) is 
completed in an automated manner. 
 
3.2.9 Hemostasis Analysis System (HAS
TM
) Analysis of Clot Formation in the 
 presence of TKS 
Analysis of platelet function, clot formation and structure was performed using the 
HAS
TM
 (Hemodyne, Inc., Richmond, VA). A mixture of 700 μl of citrated whole blood 
and 10 μl of the anticoagulant or saline (control) was co-incubated at room temperature 
for 5 minutes and then 700 μl was placed in a disposable cup. Clotting was initiated with 
addition of 50 μl of 150 mM CaCl2 to the blood – anticoagulant mixture to give a final 
CaCl2 concentration of 10 mM, while the cone was simultaneously lowered into the 
recalcified blood sample. As the clotting proceeds, platelets attach to both surfaces 
generating tension within the fibrin meshwork. This tension is measured with a 
displacement transducer in terms of platelet contractile force (PCF). The onset of PCF is 
a measure of thrombin generation time (TGT), while clot elastic modulus (CEM) is the 
ratio of the applied force (stress) by the transducer to the measured displacement (strain). 
The HAS
TM
 system operates in an automated manner until all data is collected. 
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3.3 RESULTS 
3.3.1 Structure of TKS 
TK was prepared by Kishimoto et al. in a multi-step synthesis (figure 30). Synthesis of 
TK results in generation of mixture of oligomeric species of β–O-4 type linked lignin that 
ranged up to 20 monomer units in size. TK is thus structurally homogeneous but highly 
polydispered mixture of molecules a property shared with heparins. However, the 
aromatic scaffold makes TK more hydrophobic in nature as opposed to heparins. TK 
completely lacks the anionic character that might be critical to make fruitful interactions 
with the electropositive site on thrombin. This void was filled with introduction sulfate 
moieties imparting an overall anionic feature to TK.  
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Figure 30. Schematic representation for synthesis of TKS
126
 
TK was synthesized in a multistep process, which was ultimately sulfated using TEAST-complex 
to yield TKS. 
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Figure 31. a) Standard curve generated using PSS for SEC b) SEC profiles of PSS and 
TKS.    
Chromatogram of TKS is fairly symmetrical eluting between PSS 6530 and PSS 13200 
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3.3.2 Size Determination of TKS 
Apparent molecular weight of TKS was determined with SEC using 0.1N NaOH at pH 
11.0 as an eluent. MW, MN, MP and P for TKS were calculated using PSS as a reference 
standard and were found to be 12,305 Da, 9,208 Da, 9,090 Da and 1.34 respectively. The 
chromatograms were broad and had a good symmetry, indicating the polydisperse nature 
of TKS (figure 31). Sulfated TK (TKS) retained the polydispersity as its parent TK.  
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3.3.3 Direct Inhibition Assay on Coagulation Proteinases.  
TKS showed high potency in direct inhibition of thrombin as compared to some other 
enzymes in the coagulation cascade. TKS direct inhibition of thrombin in absence of AT 
was at least 91-5,000-fold better as compared to fVIIa, fIXa, fXa and fXIa under similar 
pseudo first order experimental conditions (figure 32). In these experiments substrate 
hydrolysis of spectrozyme TH was monitored using spectrophotometer.  The residual 
proteinase activity decreased with increase in the concentration of TKS. Whereas, the 
known AT activator enoxaparin had no direct inhibitory effect on thrombin and fXa in 
absence of AT. The decrease in the proteinase activity was fitted to a logistic dose 
response equation 4 to obtain the IC50 value. TKS directly inhibits thrombin, fVIIa, fXa 
and fXIa with IC50 values of 18.7 nM, 1.70 µM, 56 µM and 90 µM respectively (Table 
09). TKS did not inhibit fIXa at all up to a concentration of 25 µM.  
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Figure 32. Inhibition of blood coagulation proteases, thrombin, fXa, fXIa, fVIIa and fIXa 
by TKS.  
TKS inhibits thrombin at an IC50 value of 18.7 nM which is at least 91-fold more potent in 
inhibiting thrombin compared to other coagulation proteases. 
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Inhibition studies were performed in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 
2.5 mM CaCl2 and 0.1 % PEG 8000 in PEG 20,000-coated polystyrene cuvettes. Spectrozyme TH 
was used as substrate and the residual enzyme activity in the presence of inhibitor was assessed by 
measuring the initial rate of substrate hydrolysis at 405 nm. Logistic equation 4 was used to fit the 
dose dependence of the residual enzyme activity to obtain log IC50, Y0, YM and HS values. See 
Methods for details. 
Errors represent ±1 SE 
 
Proteinase log IC50 (g/ml) YO YM HS IC50 (µM)
Thrombin -6.77  0.02 29  1 99  1 1.9  0.1 0.019  .001
fVIIa -4.80  0.10 31.3  3 107  5 1.2  0.4 1.70  0.10
fIXa NI 100 100 NA NA
fXa -3.30  0.60 0  0 100  4 0.5  0.2 55.7  2.0
fXIa -4.05  0.10 40  2 98  3 1.0  0.2 9.9  0.40
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 09: Inhibition of coagulation enzymes by TKS 
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3.3.4 TKS Disturbs the Catalytic Machinery of Thrombin 
To understand the molecular basis for TKS inhibition of thrombin, we studied the 
Michaelis-Menten constants derived by non-linear regression analysis of the initial rate 
versus Spectrozyme TH concentration profiles at pH 7.4 and 37 °C in the presence of 
TKS (figure 33). Plots of the initial rates versus Spectrozyme TH concentration were 
hyperbolic, as expected, from which the apparent Michaelis constant (KM,app) and 
maximal velocity of the reaction (VMAX) were derived. The results show that although the 
concentration of TKS increased from 0 µg/mL to 2.3 µg/mL (0 – 253nM), the KM,app 
value fluctuated around 1.5 μM, or alternatively remained essentially invariant in the 
range of 2.8 to 1.3 μM (Table 10). This suggests that the presence of TKS does not much 
affect the binding of the chromogenic substrate to the active site of the enzyme. In 
contrast, the VMAX value decreased steadily from a high of 25.5 mAbsU/min in the 
absence of TKS to a low of 7.4 mAbsU/min at 2.3 µg/mL TKS corresponding to a 
decrease in kCAT value from 42.8 to 12.4 s
-1
, respectively. Thus, the presence of TKS does 
not directly affect the binding of substrate in the active site but indirectly brings about 
structural changes in the active site of thrombin, which do not alter the formation of the 
thrombin–Spectrozyme TH Michaelis complex, but significantly reduce the rate of 
conversion of the complex into products. 
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[TKS]o (ng/ml) KM (µM) VMAX (mAU/min) kcat (s-1)
0 2.8  0.2 25.5  0.7 42.8  0.3
11.5 1.7  0.3 20.0  1.0 33.6  0.3
115 1.3  0.1 14.8  0.1 24.9  1.2
230 1.6  0.3 11.5  0.5 19.3  0.2
2300 1.4  0.1 7.4  0.1 12.4  0.1
KM and VMAX were measured as described in ‘Experimental Procedures’. 
Error represents 1 S.E. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10: Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis by Thrombin in the 
presence of TKS 
 
 
 
 
 
 
 
 
 
Figure 33: Michaelis-Menten Kinetics of Spectrozyme TH Hydrolysis by Thrombin in the 
presence of TKS. 
The initial rate of hydrolysis at various substrate concentrations was measured in pH 7.4 buffer 
as described in ‘Experimental Procedures’. Solid lines represent non-linear regressional fits to 
the data using the Michaelis-Menten equation.
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3.3.5 TKS Binds at the Heparin Binding Site of Thrombin  
To test whether TKS binds in one of the two anion-binding sites, we sought to measure 
the effect of a hirudin-based peptide, [5F]-Hir[54-65](SO3-), an exosite-1 binding ligand 
on the IC50 values of TKS-inhibition of thrombin. Earlier studies have shown that [5F]-
Hir[54-65](SO3-) binds thrombin with 28 nM affinity in exosite-1 with 1:1 stoichiometry 
and enhances the forward rate constant (kCAT) of Spectrozyme TH hydrolysis. Utilizing 
this knowledge we studied the competition between these two ligands by measuring the 
IC50,app values of thrombin inhibition by TKS in the presence of the dodecapeptide over a 
concentration range up to 3.2-fold higher than the KD of the thrombin-[5F]-Hir[54-
65](SO3-) complex. The IC50,app values were measured in the standard dose-response 
assay, which we had used to determine thrombin inhibition. As the concentration of the 
dodecapeptide was increased from 0 to 86nM, IC50,app essentially remained unchanged 
varying between 16 nM to 20 nM (figure 34a). This suggest that the interaction of [5F]-
Hir[54-65](SO3-) with thrombin does not affect TKS inhibition of thrombin. Thus, it 
appears that TKS does not preferentially bind thrombin in anion-binding exosite I. A 
similar enzyme inhibition study was carried out in presence of an exosite-2 binding 
ligand (figure 34b). Exosite-2 ligand like bovine heparin does not affect the proteolytic 
activity of thrombin, while TKS is a potent inhibitor. Thus, if TKS binds in or near the 
heparin binding site, its inhibition potency is expected to decrease as a function of the 
concentration of the competitor (Table 11). As the concentration of heparin was 
increased from 0 μM to 100 μM, the IC50,app values of thrombin inhibition increases from 
18 nM to 138 nM. This clearly implies that heparin is competing with TKS to bind in or 
near the anionic-binding exosite-2 of thrombin.  
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[Competitor] log IC50
(mg/ml)
Y0 YM HS IC50 (ng/ml) IC50 (nM)
0nM  -3.77  0.02 28.6  0.70 99.1  0.8 1.9  0.1 170  6.5 18.0  0.7
Hirugen
8.6nM -3.72  0.04 22.8  0.12 106  2.2 1.1  0.1 187  17.0 20.6  1.9
86nM -3.81  0.07 16.3  2.0 105  4.0 1.1  0.2 153  24.0 16.8  2.6
Porcine Heparin
0.2 μM -3.65  0.03 25.9  1.1 98.7  1.2 1.6  0.1 222  14.0 24.4  1.5
2.0 μM -3.47  0.02 26.3  0.9 97.8  0.9 1.8  0.1 340  16.0 37.4  1.8
20 μM -3.18  0.03 24.3  1.4 95.9  1.1 1.6  0.2 655  49.0 72.1  5.4
100 μM -2.90  0.05 28.2  1.8 99.7  1.0 0.9  0.1 1250  142.0 137.5  15.6
 
 
 
 
 
 
 
 
 
 
 
 
Table 11: Inhibition of thrombin by TKS in the presence of hirugen analog [5F]-Hir[54-
65](SO3-) and porcine heparin 
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Figure 34. Inhibition of thrombin by TKS in presence of exosite-1 & 2 ligands 
Competitive effect of [5F]-Hir[54-65](SO3
-
) (figure 29a) and porcine heparin (figure 29b) on 
the inhibition of thrombin by TKS. Residual thrombin activity was measured through 
Spectrozyme TH hydrolysis in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 
mM CaCl2 and 0.1 % polyethylene glycol (PEG) 8000 at 37 
O
C in the presence of 0 and 86 
nM [5F]-Hir[54-65](SO3
-
) and 0 -100 μM of porcine heparin. Solid lines represent fits using 
the logistic equation 4 to obtain the apparent IC50, as described in ‘Experimental Procedures’. 
Logistic equation 4 was used to fit the dose dependence of the residual enzyme activity to obtain 
log IC50, Y0, YM and HS values. See Methods for details. 
Error represents 1 ±S.E. 
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Figure 35: Plasma clotting assay performed using APTT and PT for TKS 
a) & b) figures represent APTT and PT results TKS. 
3.3.6 Effect on Clotting Times 
PT and APTT are commonly used to assess the coagulation status of human plasma. TKS 
exhibited a significant concentration-dependent prolongation of PT and APTT. A typical 
parameter for describing anticoagulant activity in these assays is the concentration of the 
anticoagulant needed for doubling the normal plasma clotting time (2 × PT or 2 × APTT). 
The 2 × PT and 2 × APTT value for TKS was found to be 68.6 µg/mL (7.6µM) and 23.6 
µg/mL (2.6µM), whereas that for enoxaparin was 75.3 μM and 1.2 μM respectively, 
suggesting that TKS is 9.9-fold more potent in the PT assay and approximately 2.2-fold 
weaker anticoagulant in the APTT assay as compared with enoxaparin (figure 35a & b).  
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3.3.7 Effect of TKS on whole blood clotting 
Whole blood clotting is a dynamic process that involves many components, including 
cells, which may alter anticoagulant potency. To compare TKS and enoxaparin in a 
whole blood system, we employed TEG, a technique used in clinical settings for 
following anticoagulation with LMWHs. TEG measures various responses of a formed 
clot to shearing force. In this technique, a pin is inserted into an oscillating cup 
containing whole blood. As fibrin polymerizes, the pin starts to move with the oscillating 
cup, and the movement of the pin is recorded as amplitude, which in time reaches 
maximum amplitude. The stronger the clot, the more the pin moves with the cup and the 
higher the maximum amplitude. Shear elastic modulus strength (G), a measure of clot 
stiffness, is calculated from maximum amplitude. Additionally, R and angle α are also 
obtained in a TEG experiment. R is the time required for the initial fibrin formation, 
whereas α is the acute angle in degrees between an extension of the R tracing and the 
tangent of the maximum slope produced by the TEG tracing during clot stiffening. Angle 
α is a measure of the rate of formation of three-dimensional fibrin network. Parameters 
that affect maximum amplitude include fibrin concentration and structure, concentration 
and functional state of platelets, deficiency of coagulation factors and the presence of 
clotting inhibitors. TKS affects all the parameters R, α, maximum amplitude and G 
parameters in a dose-dependent manner. Briefly, as the concentration of TKS increases 
from 0 to 414 μg/mL, R increases from 7.7 to 25.9 min. Likewise, TKS lowers the value 
of angle α from 56° for normal blood to 22° at the highest concentrations studied. This 
indicates that the kinetics of fibrin polymerization and networking is significantly 
retarded by the presence of TKS (figure 36). Enoxaparin exhibits similar characteristics, 
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except that it is 7.9-fold more potent than TKS when comparisons are made at doubling 
the R value from its value in the absence of any anticoagulants. Likewise, enoxaparin is 
12.2-fold and 12.9-fold more potent when comparisons are made for a 50% reduction in 
the angle α and shear elastic modulus G, respectively (Table 12).   
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Figure 36. Effect of TKS on clot formation in whole blood using TEG

.  
Inset in shows a typical thromboelastogram expected of any anticoagulant. MA, R, α and G are  
parameters obtained from TEG
®
 analysis. See Methods for details. Figure shows change in  
thromboelastograph as a function of increasing concentration of TKS. 
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a
TEG parameters were obtained in an automated manner from the TEG

 coagulation analyzer. 
See Experimental Procedures for a description of the setup. 
b
Reaction time R is the time interval 
between the initiation of coagulation and the appearance of first detectable signal of no less than 
2 mm in amplitude. 
c
Angle α is the acute angle in degrees between an extension of the R value 
tracing and the tangent of the maximum slope produced by the TEG

 tracing. 
d
Maximum 
amplitude (MA) is the maximum distance the pin of TEG

 moves at the end. 
e
The shear elastic 
modulus strength (G) is a calculated parameter (G = 5000MA / (100 – MA) and is a measure of 
clot strength. 
 
TEG Parametersa
conc Rb α c MAd Ge
(μM) (min) (degrees) (mm) (Dynes/cm2)
TKS 0 7.7 56.0 61.0 7821
0.0171 8.9 50.5 50.5 7658
1.71 13.2 42.5 57.0 6628
8.6 16.9 43.0 55.5 6236
17.1 25.9 22.0 41.5 3547
Enoxaparin 0 7.0 59.0 56.5 6456.5
0.3 8.0 49.0 51 5204.0
0.44 9.5 39.5 51 5204.0
0.6 11.5 43.0 47.0 4434.0
0.75 14.0 41.0 46 4259.5
0.89 17.0 36.5 47.0 4434.0
1.0 17.0 31.5 42.0 3620.5
Table 12: Parameters obtained from thromboelastograph (TEG

) study of TKS and  
enoxaparin in human whole blood.
a 
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To further compare the whole blood anticoagulant potential of TKS with enoxaparin, we 
performed an ex-vivo study using HAS, which measures the forces generated by platelets 
within a clot. In this technique, the clot is allowed to form between a temperature 
controlled lower surface (cup) and a parallel upper surface (cone). As the clot grows, it 
attaches to both the surfaces, pulling the fibrin strands inward. This pull is measured by a 
displacement transducer, which produces an electrical signal on the cone proportional to 
the amount of force generated by the platelets. HAS also provides detailed information on 
clot structure through the measurement of CEM, which is the ratio of stress induced by 
platelets to strain arising from the change in clot thickness. PCF is observed to increase as 
soon as thrombin is formed, suggesting that the appearance of PCF can be used as 
surrogate marker for TGT, the minimal time required for production of thrombin 
following initiation of clotting. In addition to its dependence on thrombin, PCF is 
sensitive to platelet number, platelet metabolic status, presence of thrombin inhibitors and 
the degree of glycoprotein IIb/IIIa exposure. Likewise, CEM is a complex parameter that 
is sensitive to changes in clot structure, fibrinogen concentration, the rate of thrombin 
generation and red blood cell flexibility, whereas TGT is sensitive to clotting factor 
deficiencies, antithrombin concentration and the presence of anticoagulants. Low PCF 
and CEM coupled with a prolonged TGT are associated with increased bleeding risk, 
whereas elevated PCF and CEM paired with a decreased TGT are associated with 
thrombotic disease states. TKS affects TGT, PCF and CEM parameters in a dose-
dependent manner with 6.7 μM TKS required to double the TGT value using HAS. This 
effect parallels the results obtained in TEG. More importantly, the presence of TKS in 
blood decreases PCF from 8 to 0.66 kdynes at 8.3 μM (figure 37a), whereas enoxaparin 
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Figure 37. Effect of TKS on platelet function in whole blood using HAS™.  
HAS™ profiles obtained with show the variation in a) PCF and b) CEM, as a function of 
concentration of TKS.  
induces a PCF of 0.66 kdynes at 0.47 μM, a difference of 17.7-fold. Likewise, TKS 
decreases CEM from 18.25 kdynes/cm
2
 for normal blood to 0.62 kdynes/cm2 at 8.3 μM 
(figure 37b). Comparison of TKS for a 50% reduction in CEM values indicates that 
enoxaparin is 23.5-fold more potent than TKS (Table 13). These results confirm that 
TKS behaves in a manner similar to enoxaparin, except for the concentration at which it 
is effective. When compared with FDS, TKS has slightly better potency in whole blood, 
1.4 – 2.9-fold based on the parameter evaluated. This slight reduction in potency can be 
attributed to the more heterogeneous nature of FDS, which is structurally more diverse 
than TKS.  
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HAS™  Parametersa
Conc TGTb PCF c CEMd
(µM) (min) (Kdynes) (Kdynes/cm2)
TKS 0.0 6.25 8.00 18.25
0.008 5.05 7.27 12.00
0.83 6.55 5.82 6.31
4.17 11.25 3.30 3.94
8.3 13.55 0.66 0.62
Enoxaparin 0.0 3.55 7.60 21.60
0.146 5.15 5.30 15.10
0.218 9.05 3.60 12.70
0.346 11.00 2.80 8.50
0.437 12.45 0.90 2.90
aHAS™ parameters were obtained in an automated manner from the Hemostasis Analysis 
System. See Experimental Procedures for a description of the setup. 
b
Thrombin generation 
time is the time interval between the initiation of coagulation and the onset of detectable 
platelet contractile force. 
c
Platelet contractile force describes the forces generated by platelets 
during clot retraction. 
d
Clot elastic modulus is the ratio of the applied force (stress) to the 
measured displacement of the clot. 
 
Table 13: Parameters obtained from the Hemostasis Analysis System (HAS™) study of 
TKS and enoxaparin in human whole blood.
a
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3.4 Discussion 
In an effort to mimic heparin’s structural features we have reported at least 3 different 
types of carboxylated lignins. All three were a fairly complex mixture of molecules 
arising from different sizes and linkage types. Further, we studied the size based potency 
of one of the better DHPs, FD while still retaining the structural heterogeneity. In our 
continuing efforts to achieve relevant and meaningful information out of this complex 
mixture we have synthesized structurally homogenous lignin-like mixture. The main 
difference from the earlier DHPs is the lack of carboxylic acid functionality, which has 
been replaced by sulfates to achieve an overall anionic nature.  
 
While conducting the literature search for synthesis of a β-O-4 type lignin polymers we 
stumbled across Kishimoto and co-workers who have already synthesized this 
structurally homogenous mixture.
126
 Before going through an arduous task of multi-step 
synthesis we obtained 100 mg sample from Dr. Kishimoto’s group as a generous gift. 
Note: A fellow graduate student, Akul Mehta is currently working on synthesis of TK to 
generate larger amounts to be studied in animal models.  
 
TK polymer received as a gift was subjected to sulfation using TEAST complex to yield 
TKS. The molecular weight characteristics of TKS were evaluated using SEC. The MN 
and MP were found to be 9,208 and 9,090 respectively suggesting that there is equal 
distribution of samples on either side of the bell shaped curve indicative of a symmetric 
chromatogram.  The polydispersity derived from the relationship between MW (12,305) 
and Mn (9,208) indicated that TKS like DHPs are polydisperse in nature with a P value 
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of 1.34. When compared with DHPs (P = 2.0 - 4.0) TKS is fairly less polydisperse 
implying the advantage of controlled polymerization over random polymerization. When 
DHPs are formed the enzyme horse radish peroxidase (HRP) randomly couples the 
monomers to generate β-O-4 and β-5 linked structures as opposed to synthetically made 
TKS, where the linkages are formed as directed to yield just the β-O-4 type polymer. 
Using the per sulfated form of the starting monomer the apparent chain length was 
calculated to be 25.  
 
Since TKS was a result of the complex DHP mixture of FA, we opted first to evaluate 
TKS for direct inhibition of the coagulation factors in the common pathway rather than 
conduct the APPT and PT assays. TKS potently inhibited thrombin with an IC50 of 18.7 
nM, which is a 2.7-fold improvement over the most potent sulfated FD. Interestingly, 
TKS could inhibit fXa only at a very high concentration of 56µM. This is a 3000-fold 
increase, which indicates the excellent specificity of TKS for thrombin over fXa. To 
probe into the specificity of TKS, which lacks the carboxylic acid group we chose to 
screen several other important factors in the coagulation cascade. The IC50 values 
obtained for inhibition of fVIIa, and fXIa were 1.7 µM and 90 µM and TKS completely 
failed to inhibit fIXa at concentrations as high as 25 µM. TKS inhibition for fVIIa and 
fIXa being 94.4-fold and 5000-fold weaker than thrombin strengthens the conclusion that 
indeed TKS is a specific inhibitor of thrombin. Probably, this also implies that thrombin 
specificity arises due to the structural uniqueness of TKS, which possess only the β-O-4 
type linkages and not due to the absence of carboxylic acids. Presence of sulfates instead 
of carboxylic acid imparting such a huge specificity in inhibition seems highly unlikely, 
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though it remains to be determined if it was true. Also, from our previous work on 
sulfated and unsulfated DHP fractions it is evident that there is none to insignificant 
change (1.07 to 1.4-fold) in the specificity with the introduction of sulfates.       
 
To understand the mechanism of inhibition of TKS by which it brings about the change 
in binding of the substrate at the active site we chose to study all three potential binding 
sites on thrombin. We performed Michaelis-Menten type kinetics to investigate the active 
site binding phenomenon and competitive ligand binding studies to probe the allostericity 
for exosite-1 and 2. TKS did not compete with the substrate during binding but it brought 
about the change in the hydrolysis of the substrate through allosteric modulation. This 
was apparent by the decrease in the VMAX and KCAT values, whereas the Michaelis-Menten 
constant remained unchanged. The competitive ligand binding studies with site specific 
ligands [5F]-Hir[54-65](SO3-) (exosite-1) and heparin (exosite-2) revealed that TKS 
competes with heparin to bind at the exosite-2 of thrombin. This was concluded based on 
worsening of the IC50,app values for TKS inhibition of thrombin with increasing 
concentration of exosite-2 competitor. And in case of exosite-1 ligand a very insignificant 
change in the IC50,app values was observed. At this point it is important to recall that both 
the exosites are electropositive with exosite-2 being less compensated and less 
hydrophobic than exosite-1.  
 
We further evaluated TKS for their effect as an anticoagulant in human plasma and whole 
blood. This is an important study that had to be undertaken considering the fact that 
heparins and LMWH non-specifically bind to plasma proteins resulting in the numerous 
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side effects they carry. The plasma anticoagulation effect of TKS was tested using APTT 
and PT assays, which would assess its ability to work via the intrinsic and the extrinsic 
pathway of the coagulation system. Comparative studies with enoxaprain, a LMWH 
revealed that TKS was 2.2-fold weaker in the APTT assay, while it was 9.9-fold more 
potent in acting through the extrinsic pathway. Based on these comparisons it is hard to 
conclude if TKS evades non-specific interactions with the plasma proteins as both 
enoxaparin and TKS work through a complete different mechanism. A similar study 
using an FDA approved DTI would yield a more relevant comparison. Nevertheless, the 
plasma study indicates that TKS still retains its anticoagulant potency when subjected to 
a higher system like plasma. Also, when compared with the most potent sulfated FD 
fraction, TKS has essentially same effect on APTT and PT implying a cumulative effect 
in case of DHPs, which works through thrombin and fXa.  Hence, we can conclude that 
though TKS is more potent in inhibiting thrombin as compared to DHPs they bring about 
the same effect in higher systems like plasma through a complete different mechanism. 
 
Based on the results achieved from plasma studies TKS was subjected to a more complex 
system to prove its anticoagulant potency. Whole human blood assays performed using 
TEG® and HAS™ indicated that TKS was 7.9-12.9-fold and 17.7-23.5-fold less active in 
comparison with enoxaparin. It is possible that the significant hydrophobic character of 
TKS induces binding to cells resulting in significant sequestering of active agent. It is 
likely that this non-specific binding will be reduced with less polydisperse, synthetic 
small molecules. 
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Overall, TKS demonstrates a major improvement over DHPs in terms structural 
homogeneity, which has led to a greater specificity in targeting thrombin. It also 
possesses a better plasma and whole blood anticoagulation activity suggesting the 
reduction in the non-specific binding of the plasma proteins. Toxicity studies have to be 
performed to ascertain that TKS do not induce abnormal effects.  
 
3.5 Conclusion 
The entire study points towards specificity of TKS, which arises due to the β-O-4 type of 
linkage. Our DHPs are structural heterogeneous leading us to believe that structural 
features like the linkages are dictating the specificity in targeting enzymes. We cannot 
hold back to hypothesize that β-5 type linkages, which is the second most abundant in 
lignin and our enzymatically synthesized DHPs might be fXa specific. This hypothesis if 
proven would revolutionize the entire process of anticoagulant drug design. Also, studies 
from the previous chapter indicate that an octamer might be the optimum working range. 
Utilizing the information from these studies a tetramer of β-O-4 type synthesized would 
be an appropriate chain length to start with, which can be easily converted to an octamer 
by combining the two tetramers. Further, slight functional group modification might be 
essential to achieve greater potencies. By and large, this study puts forward a new class 
of molecule as a potential anticoagulant.  
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CHAPTRT 04 
Non-sulfated Cinnamic Acid-Based Lignins As Potent Antagonists of HSV-1 Entry 
Into Cells 
 
4.1 Background 
4.1.1 Introduction 
Herpes viruses are a leading cause of human viral disease, second only to influenza and 
cold viruses. They are capable of causing overt disease or remaining silent for many 
years only to be reactivated. The herpes family contains more than hundred viruses that 
infect organisms of which eight are known to infect human beings. In general herpes 
viruses cannot survive at room temperature, especially outside of the body where they 
can dry out. Direct contact between susceptible cells and secretions of infected cells is 
usually required for transmission. The herpes virus has an excellent ability to remain 
dormant for years and the sporadic reappearance of herpetic lesions is a perturbing aspect 
of the infection.
127-128
 For reasons that are poorly understood the latent, inactive, infection 
can become active and cause illness. Reactivation of dormant viruses occurs when they 
start to reproduce inside cells, eventually causing them to burst and spread the virus 
particles to propagate infection.
129
 The virus particles can also attack neurons causing 
neurotropic disorders. Breakage of latency can occur in these cells and the virus can 
travel back down the nerve axon, where lesions are seen.
130
 This means that recurrence of 
infection (and therefore symptoms) can occur at the same site as the initial infection. 
There are several agents that seem to trigger recurrence, most of which are stress-related. 
It also appears that exposure to strong sunlight and perhaps fever can lead to recurrence. 
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These factors may cause some degree of immune suppression that leads to renewal of 
virus proliferation in the nerve cell. 
 
Herpes infections are highly prevalent affecting at least 1 in 3 individuals in the US. Of 
the eight strains known to infect humans, herpes simplex virus, HSV-1 and HSV-2 are 
the most common ones. Refer Table 14 for the list of 8 strains of herpes virus and their 
site of latency. The primary difference between the two is their “site of preference” when 
establishing latency in the body.
131
 HSV-1 usually establishes latency in the trigeminal 
ganglion, a collection of nerve cells found in close proximity to the ears and recurring 
herpes outbreaks will commonly occur around the mouth or facial region. HSV-2 usually 
establishes latency in the sacral ganglion, a collection of nerves found at the lower base 
of the spine and recurring outbreaks will commonly occur in the genital region. Though 
this is the most commonly noted difference, it is not absolute. Both HSV-1 and HSV-2 
can reside in either or both parts of the body and infect orally and/or genitally. 
 
HSV-1 is often transmitted in childhood through kissing, but can be transmitted at any 
age through direct skin-to-skin contact. In the US about 50% of adults are carrier of 
HSV-1 antibodies by the time they are young adults and by the time they are 50 years 80-
90% of Americans carry HSV-1 antibodies.
132
 For both types, at least two-thirds of 
infected people have no symptoms, or symptoms too mild to notice such as cold sores. 
However, both types can recur and spread even when no symptoms are present. 
Occasionally, the virus spreads to the central nervous system causing meningitis or 
encephalitis. So far, vaccines, ILs, IFNs, therapeutic proteins, antibodies, 
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immunomodulators and small-molecule drugs with specific or non-specific modes of 
action lacked either efficacy or the required safety profile to replace the nucleosidic drugs 
acyclovir, valacyclovir, penciclovir and famciclovir as the first choice of treatment.
133-135
 
All of these drugs are classified, as “Nucleoside Antimetabolites” and they are inhibitors 
of viral DNA polymerase. These drugs are phosphorylated by viral thymidylate kinase to 
the monophosphate, which is further bioactivated to the triphosphate. The triphosphate is 
selective inhibitor of viral DNA polymerase. 
 
4.1.2 Diseases caused by the Herpes virus 
Oral herpes, Herpes keratitis, Herpes whitlow, Herpes gladiatorum, Eczema herpeticum, 
Genital herpes, HSV proctitis, HSV Encephalitis, HSV Meningitis, HSV infection of 
neonates (This results from HSV-2 and is often fatal, although such infections are rare. 
Infection is especially possible if the mother is shedding virus at the time of delivery). 
 
Table 14: Types of herpes viruses infecting humans and the site of latency  
Acronym Name Site of Latency 
HSV-1 Herpes Simplex Virus 1 Sensory Neurons 
HSV-2 Herpes Simplex Virus 2 Sensory Neurons 
VZV Varicella-Zoster Virus Sensory Neurons 
CMV Cytomegalo Virus Monocytes, Endothelial 
cells 
EBV Epstein Barr Virus B Lymphocytes 
HHV-6 Human Herpes Virus 6 T cells, Monocytes 
HHV-7 Human Herpes Virus 7 T cells, Monocytes 
HHV-8 Kaposi Sarcoma Associated Virus Monocytes ? 
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4.1.3 Structure of Herpes Virus 
 
 
 
 
 
 
 
 
 
Figure 38. General structure of the herpes virus 
 
The general structure of the herpes virus consists of the following: (refer figure 38) 
 
Envelope 
Herpes viruses are enveloped viruses with close to a dozen glycoproteins attached to the 
cell surface. They bud from the inner nuclear membrane, which has been modified by the 
insertion of herpes glycoproteins. These glycoproteins determine the cell to be infected. 
The viral membrane is quite fragile and a virus with a damaged envelope is not 
infectious. Besides drying, the virus is also sensitive to acids, detergents and organic 
solvents as might be expected for a virus with a lipid envelope. 
 
 
lipid bilayered 
envelope 
glycoproteins 
capsid 
tegument 
double 
stranded  
DNA 
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Tegument 
The space between the envelope and the capsid is the amorphous tegument. This contains 
virally-encoded proteins, such as VP16 and vhs (virus host shut off), and enzymes that 
are involved in the initiation of replication. 
 
Capsid 
These viruses have a doughnut shaped capsomere of about 100-200 nm in diameter with 
an icosahedral proteinaceous nucleocapsid. The latter contains 162 capsomeres or 
morphological elements. 
 
Genome 
Inner core of the herpes viruses have a linear double stranded DNA viral genome 
encoding about 100-200 genes. Many of these proteins (about half) are not directly 
involved in the virus structure or controlling its replication, but function in the interaction 
with the host cell or the immune response of the host. HSV-1 and HSV-2 have 
characteristic resemblances in their genome. The genome of HSV encodes a number of 
enzymes: DNA-dependent DNA polymerase, thymidine kinase (phosphorylates 
thymidine and other nucleosides), ribonucleotide reductase (converts ribonucleotides to 
deoxyribonucleotide) and serineprotease (converts a scaffolding protein to its final form). 
The genome also encodes 11 surface glycoproteins. These are involved in attachment 
(gB, gC, gD and gH), fusion of the viral membrane with that of the host cell (gB, gH and 
gL), immune escape and other functions (gC, gE and gI), production of virus in cell 
culture (gK), and unknown function (gG, gJ and gM).
136-145
 
102 
 
4.1.4 HSV-1 Infection  
HSV-1 infection of cells can be divided into two phases, the binding phase and the 
penetration phase (figure 39). The first phase involves the binding of the viral 
glycoprotein gC and/or gB to the glycosaminoglycans (GAGs) chains on cell surface 
proteoglycans.
146-148
 The major type of GAG chain found on the cell surface is heparan 
sulfate (HS). This initial binding is not sufficient for viral penetration, which further 
involves fusion of the viral envelope with the cell membrane. This step involves 
interaction of viral glycoprotein gD with one or several receptors for gD on the cell 
surface, before the viral particle can fuse with the cell plasma membrane and the viral 
capsid is released into the cytoplasm. The fusion process is a complex set of events 
involving multiple interactions between various gD receptors on the cell surface and the 
viral glycoprotein gD, gB and hetero-oligomers of gH and gL. Depending on the nature 
of interaction and size of HS chain, a single chain may bind multiple viral ligands on a 
virion.
149-151
 The entry receptors discovered to date fall into three categories. They 
include HVEM (herpes virus entry mediator), a member of TNF receptor family, nectin-1 
and nectin-2, members of the immunoglobin superfamily and specific site in HS 
generated by certain 3-O-sulfotransferases (3-OST).
152-160
 
 
 
 
 
103 
 
 
Figure 39. Pictorial representation of the mechanism of herpes virus entering into human 
cell. 
 
 
4.1.5 Evidence Showing Role of HS 
There is convincing evidence indicating that HS is critical for HSV-1 adsorption on the 
cell surface and its subsequent entry into cells.
161-162
 First, cells that are devoid of HS (but 
not other GAGs) because of enzymatic treatment or genetic mutation are markedly less 
susceptible to HSV-1. These cells have greatly reduced number of receptors for viral 
binding. It has been shown that HSV-1 attaches weakly to HS-deficient Chinese hamster 
ovary (CHO) cells.
163-164
 Second, soluble heparin, which is structurally similar to HS, 
inhibits binding of viruses to cells, whereas the structurally less similar GAG chondroitin 
sulfate fails to inhibit binding or infection. Third, gC and gB bind selectively and 
independently to heparin-sepharose columns under physiological conditions. Also, degree 
of sulfation of GAGs is an important determinant for recognition by viral glycoprotein 
gB2.
165
 Heparin, which has higher degree of sulfation as compared to HS, is a better 
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competitive inhibitor of gB2 binding.
166
 In 2002, Liu et.al have characterized a HS-based 
octasaccharide that binds to HSV-I gD.
167
 The distinguishing feature in the composition 
of the octasaccharide is the presence of 3-O-sulfate glucosamine residue, which is an 
uncommon structural modification in heparin sulfate. Its presence in the HSV-I gD 
binding sequence must probably confer specificity of interaction by generating a unique 
protein binding site, hence assisting HSV-I entry into the cell.
168
 Thus, HS is required for 
both viral binding and penetration –the two early events in infection. HS also plays 
important role in attachment of other viruses such as the human immunodeficiency virus 
(HIV) (E gp120 and gp41), dengue virus (gC, gE and gM), foot and mouth disease virus 
(E VP1-4), vaccinia virus (E A27L), Sindbis virus (E2 glycoprotein), respiratory 
syncytial virus, and Echovirus.
169-174
 In each of these viruses, cell surface HS is used for 
gaining entry into the cell. 
 
4.1.6 Heparan Sulfate 
HS is the most complex polysaccharide on the surface of the mammalian cells. GAG 
polysaccharides are long, polyanionic chains consisting of repeating disaccharide units.
175 
HS is a GAG covalently attached to the protein core (in the cell membrane - syndecan-1, 
N-syndecan, fibroglycan, amphiglycan and glypican) of proteoglycans, which are 
expressed on nearly all cell surfaces, in the extracellular matrices and are even segregated 
into intracellular granules.
176-177
 Structurally, HS is a heterogeneous linear co-polymer of 
glucosamine (GlcNp) and glucuronic acid (GlcAp) residues linked in a 1-4 manner, of 
which the GlcNp residues are typically acetylated at 2- position (figure 40).
178
  Despite 
this apparently simple monomeric disaccharide structure, HS perhaps represents the most 
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Figure 40. General structure of heparan sulfate showing the disaccharide unit, glucosamine 
and uronic acid residues linked in a 1-4 manner  
 
structurally complex molecule nature biosynthesizes because of two critical, essentially 
incomplete,  
 
 
 
 
 
 
 
 
 
structure modification steps. One, some GlcAp residues are epimerized to iduronic acid 
(IdoAp) and two, incomplete sulfation occurs at the 3-O-, 6-O-, and 2-N positions of 
GlcNp in addition to sulfation at 2-O-position of few IdoAp residues.
178
 This primary 
structural diversity is further complicated by another level of complexity wherein sulfate 
groups may cluster in small regions and form differentially charged domains. The 
number of structural sequences possible with these variations, especially taking into 
account the size recognized by proteins and receptors run into millions. The final 
structure of HS depends upon the incompleteness of the reactions that occur during the 
biosynthetic process. The modification process is more complete in heparin where the 
final disaccharide IdoAp(2-OSO3)-GlcNpSO3(6-OSO3) represents up to 70% of the chain, 
leading to a heavily O-sulfated polysaccharide with a high IdoAp/GlcAp ratio. In 
contrast, the modifications that occur during the biosynthesis of HS are less extensive; 
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leading to HS molecules characterized by lower IdoAp content and a lower overall 
degree of O-sulfation and resulting in high heterogeneity of distribution of the sulfate 
groups along the chain.
179-182
 This diversity arguably plays a key role in numerous 
biological processes like maintaining cell surface architecture; modulating critical 
biological events and also interacting with a variety of ligands. Typical concentrations of 
HS proteoglycans on the cell surface are in the range of 10
5
-10
6 
molecules/cells as 
measured in various cell culture systems. The interactions are largely electrostatic in 
nature and depend on the distribution of hexuronic acid residues and sulfate groups along 
the polysaccharide chain.  The prolific expression of HS and their strong interactive 
ability are two features that have made them attractive adhesion molecules providing 
initial docking sites for all sorts of viruses and other microorganisms during their 
evolution. In addition, the negative charge arising from sulfates/carboxylates on HS 
makes it well suited to interact with positively charged basic amino acid domains on viral 
proteins. 
 
4.1.7 HS Mimics 
HS plays a vital role in the entry of the HSV-1 into cells. Thus, structural or functional 
mimics of HS are likely to competitively inhibit the entry of the virus into cells. In this 
context, numerous sulfated molecules have been explored as mimics of HS in the 
inhibition of HSV-1 entry into cells (figure 41).
183
 These include heparin and its 
chemically modified derivatives, non-anticoagulant heparin, pentosan polysulfate, 
dextran sulfate, sulfated maltoheptaose, fucan sulfate, fucoidans, spirulan, sulfated 
galactans, and miscellaneous sulfated polysaccharides.
184-186
 These compounds compete 
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with cell surface HS for binding to the virus particles and therefore are most active when 
present during the attachment phase of the viral entry. Not unexpectedly, each HS mimic 
found to-date as an inhibitor of viral entry has a linear polysaccharide backbone with 
varying degrees of sulfation.  
 
 
 
 
 
 
 
 
 
 
 
Figure 41. Some of the sulfated polysaccharides that have been tried as heparan sulfate 
mimics for HSV-1 inhibition activity. 
 
 
A study of molecular weight dependence of infection inhibition activity shows that the 
antiviral potency increases with increasing sulfation levels and length of chain. Yet, 
detailed aspects of interactions at molecular level, their nature and contributions, the 
order of interactions, and the step-wise molecular mechanism remains unclear. 
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4.2 Rationale 
From the literature study, it is clear that HS on the cell surface plays an imperative role in 
assisting the entry of the HSV-1 into cells. Therefore, designing a drug that would inhibit 
the entry of the virus at the very first stage and thus preventing any further proliferation 
seems crucial. A simple rational drug approach that comes to mind is designing HS 
mimics that would competitively inhibit the entry of the virus into cells. Literature survey 
shows that HS mimics have been developed to competitively inhibit viral entry. 
However, most HS mimics reported so far have been polysaccharide-based sulfated 
molecules. In an effort to discover non-polysaccharide-based macromolecular mimics of 
HS, we previously designed sulfated lignins, which are sulfated derivatives of the natural 
biopolymer lignin.
123-124,187-188
 Lignin is a complex, heterogeneous polymer made up of 
repeating phenylpropanoid units containing multiple hydroxyl groups (figure 42).
189-190
 
Our sulfated lignins were found to be excellent antagonists of HSV and HIV infections of 
cells.
187-188
 Although the biochemical chemical basis for the anti-HSV and anti-HIV 
activity of sulfated lignins is not known, a plausible hypothesis relies on the similarity of 
sulfated lignin’s electrostatic surface with that of HS.123 In contrast to sulfated 
polysaccharide, the sulfated lignin scaffold that we proposed is an attractive alternative 
because its phenylpropanoid units afford numerous opportunities for structural variations 
to fine-tune biological activity. In addition, lignin can be rather easily synthesized in high 
yields in the laboratory using enzymatic oxidative coupling. We reasoned that it should 
be possible to devise a lignin scaffold that is completely devoid of sulfate moieties and 
yet possess an electrostatic surface equivalent to that of HS so as to retain potent 
antagonism of viral entry into cells. The average negative charge density of HS is nearly 
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1.0-1.4.
189-193
 Thus, a lignin monomer containing one negative charge, which is not a 
sulfate, for example, caffeic or ferulic acid is likely to afford a nonsulfated lignin polymer 
with HS mimicking properties (figure 43).  
 
We found that the two carboxylated lignins are not only potent inhibitors of HSV-1 entry 
into mammalian cells, but are much more effective than sulfated lignins. In addition, the  
 
 
 
 
 
 
 
Figure 42. Monomers which serve as the precursor for lignin biosynthesis 
 
 
results show that the shorter carboxylated lignins are very potent in preventing HSV-1 
infection suggesting the possibility that structural features, in addition to carboxylate 
groups, may be important. The results present major opportunities for developing orally 
available small molecular weight lignin-based antiviral strategies. 
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Figure 43.  Structure of carboxylated lignins CD and FD obtained from horseradish 
peroxidase-catalyzed oxidative coupling of caffeic and ferulic acid, respectively.  
Carbon designations (α, β, 4, 5, and others), unique to the lignin field, are as shown. X can be 
either -H or -OH. Oxidative coupling through radical intermediates give rises to oligomers with 
different types of intermonomeric linkages. The most common linkages formed include β-O-4 
and β-5. Other less common linkages include β-β, 5-5, and 5-O-4, for which oligomerization 
tends to arrest chain growth.(ref) The length of the chain greatly depends on the conditions of 
oligomerization.  
 
 
4.3 Experimental Methods 
4.3.1 Chemicals, Cells, and Viruses  
Horseradish peroxidase (HRP) with activity of 250-330 units/mg was from Sigma (St. 
Louis, MO). β-Galactosidase substrate o-nitrophenyl β-D-galactopyranoside (ONPG) was 
performed from Pierce (Rockford, IL). High purity water, obtained from NERL 
Diagnostics (RI, U.S.A.), was used in all experiments. Dr. Patricia Spear (Northwestern 
University, Chicago) provided HeLa cells and the HSV reporter viruses listed here. HSV-
1 virus strain carrying the lacZ gene of E. coli and capable of expressing β-galactosidase 
as a reporter of entry included HSV-1(KOS) gL86.
193-194
 Polystyrene sulfonate standards 
111 
 
(PSS) (4-33 kDa) were from Sigma (St. Louis, MO). Other chemicals and solvents used 
in the work were purchased from either Sigma-Aldrich (St. Louis, MO) or Fisher 
(Agawam, MA). 
 
4.3.2 Synthesis of Carboxylated Lignin Polymers  
The lignin polymers from caffeic acid and ferulic acid monomers, CD and FD, 
respectively, were prepared in a manner following earlier work.
123-124
 Briefly, caffeic acid 
or ferulic acid (25 mM, 200 mL) and H2O2 (75 mM, 100 mL) were added dropwise to a 
50 mL solution of 10 mg HRP in 10 mM sodium phosphate buffer, pH 8.0, over a period 
of 5 h at room temperature in dark. Three additional aliquots H2O2 (75 mM, 100 mL) 
were added over the next 72 h. At the end of polymerization the solution was freeze-dried 
to obtain approximately 2 g of CD and FD polymers.  
 
4.3.3 Fractionation of CD and FD Using Centrifugal Filtration.  
The polymerization reaction mixture (~2 g) was dissolved in deionized water (8 mL) and 
filtered through Millipore filter (NMWC 30 kDa) at 4000 g. Filtration was continued 
until the retentate volume was approximately 200 μL. This process was repeated three 
more times and the final retentate was labeled as F30 fraction. The filtrates from the 
above process were pooled, lyophilized, redissolved in deionized water and then further 
fractionated in the manner described above using a 10 kDa filter. The retentate so 
obtained was labeled as F10 fraction. This process was repeated to obtain F5 and F3 
fractions using 5 and 3 kDa membranes. The retentates were collected and lyophilized to 
obtain four fractions in yields of 15-20, 5-8, 3-5, and 1-2%, respectively. 
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MN = 
∑ Ai × Mi
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P = 
MW
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MW = 
∑ Ai × Mi
2
∑ Ai × Mi 
4.3.4 Determination of Molecular Weight of Carboxylated Lignin Fractions 
The number and weight average molecular weight of CD and FD fractions was measured 
using gel permeation chromatography (GPC) on a Shimadzu chromatography system 
composed of LC10Ai pumps and a SPD-10A VP UV-vis detector controlled by a SCL-
10A VP system controller connected to a computer. Each fraction was analyzed using 
Phenogel 5 μ (Phenomenex, Torrance, CA, 7.6 mm i.d. x 300 mm). The mobile phase 
consisted of 100% tetrahydrofuran at a constant flow rate of 0.7 mL/min. Polystyrene 
standards, caffeic acid, and ferulic acid were used for calibration purposes. The 
relationship between logarithm of the molecular weight and the elution volume (V) of the 
standards was found to be linear with a correlation coefficient of 0.99. The wavelength of 
detection for CD and FD fractions was set at 280 nm. Each chromatogram was sliced into 
1000 time periods providing 1000 MR with the corresponding absorbance (A) values. 
These values were used to calculate number average molecular weight (MN), weight 
average molecular weight (MW) and polydispersity (P) parameters from equations 1, 2, 
and 3, respectively, for each CD and FD fraction.  
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Y =  YO +
YM − YO
1 + 10(log[L]O − log IC50) × HC
…... (4) 
4.3.5 Assay for HSV-1 Entry into Cells 
Assays for infection of cells were based on the quantification of β-galactosidase 
expressed by the mutant HSV viral genome containing the lacZ gene, as described 
earlier.
195-196
 HeLa cells were grown in 96-well tissue culture dishes (2-4 x 10
4
 
cells/well), washed after 16 h of growth, and exposed to 10 plaque forming units (PFU) 
per cell of the HSV virus in 50 μL of phosphate-buffered saline (PBS) containing glucose 
and 1% calf serum for 6 h at 37 °C. To test for inhibitory activity, the sulfated 
compounds were simultaneously added to this 50 μL medium in varying amounts ranging 
from 0 to 2 μg. Following incubation, the cells were solubilized in 100 μL of PBS 
containing 0.5% NP-40 and 10 mM ONPG. The initial rate of hydrolysis of the substrate 
was monitored spectrophotometrically at 410 nm, which corresponds to the expressed 
level of β-galactosidase within HeLa cell. The initial rate of hydrolysis of the substrate in 
the absence of any added antagonist was used as the control and assigned a value of 
100% HSV infection. Assays were performed in duplicate. Logistic equation 4 was used 
to fit the dose-dependence of HSV infection to obtain the IC50. 
 
 
 
 
 
In this equation, Y is the observed β-galactosidase activity (in %) in the presence of 
carboxylated lignin (L) to that in its absence, YM and Y0 are the maximum and minimum 
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possible values of the β-galactosidase activity, IC50 is the concentration of L that results 
in 50% antagonism of HSV-1, and HC is the Hill Cooperativity Index. 
 
4.4 Results and Discussion 
4.4.1 Caffeic and Ferulic Acids Polymerize with Ease To Generate Long Chains 
Enzymatic polymerization of phenylpropenoid monomers to produce synthetic lignins 
has been explored for a long time.
197-201
 Yet, previous reports on the oxidative coupling 
of 4-hydroxycinnamic acids resulted only in oligomers with an average chain length of 
less than three monomers.
202-203
 HRP-catalyzed polymerization of caffeic and ferulic acid 
monomers at pH 8.0 with gradual addition of H2O2 over a period of more than 3 days 
resulted in CD and FD polymers, respectively, in nearly quantitative yields (See figure 
43). The MN and MW values of these polymeric mixtures, measured using GPC, were 
found to be 4264 and 13272 Da for CD and 5322 and 11525 Da for FD (Table 15). These 
values indicate that CD is more polydisperse and probably more heterogeneous than FD. 
The average chain length of the two polymers was found to be 12 (CD) and 29 (FD). This 
is the first report of such long polymers obtained through enzymatic polymerization of 4-
hydroxycinnamic acids. A probable reason for the higher level of polymerization is the 
higher concentration of enzyme used in the reaction as well as the prolonged addition of 
the oxidant. 
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Table 15. Physical Properties of Size Fractionated Carboxylated Lignins 
 
 
 
 
 
 
a
Number, weight, and peak average molecular weights were obtained by GPC analysis. 
b
Polydispersity. 
c
The peak average chain length was calculated from the ratio of MP and 
molecular weight of the two monomers. Numbers in brackets refer to the range of chain lengths 
(see Experimental Methods). 
 
4.4.2 CD and FD Are Less Globular than Natural Lignins 
To assess the size dependence of putative antiviral activity of CD and FD, the two 
polymeric mixtures were separated into four fractions of varying sizes using 3K, 5K, 
10K, and 30K membrane-based centrifugal filtration. The GPC profiles of fractions were 
found to be broad and reasonably symmetrical (figure 44). This implied that each 
fraction contained nearly all types of chains. For example, although the average chain 
length of FD3 and CD3 is 3.6 and 4.7, both fractions contain chains as long as 27 and 12 
units, respectively (Table 15). Thus, the difference between the membrane-separated 
fractions arises primarily due to chains being present in different proportions. A probable 
explanation for why high molecular weight chains are present in CD3 and FD3 fractions 
is that carboxylated lignins are more linear polymers than natural lignins. The random 
oxidative coupling mechanism of enzymatic polymerization affords chain elongation 
along nonlinear centers resulting in multidimensional polymerization
189-190
 which can 
generate globular structures. Globular structures typically cannot pass through molecular 
membranes or sieves. In contrast, linear structures can pass through sieves through 
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reptile-like motion. Thus, carboxylated lignins appear to be less globular than natural 
lignins. This is important because greater the linearity of the lignin polymer greater is its 
probability of mimicking HS, which has a 100% linear structure. 
 
The MN, MW, and polydispersity (P) values calculated from the GPC profiles confirm the 
above conclusions. The MN values ranged from 1052 to 7558, while MW was found to be 
in the range of 2084 and 16464 (Table 15). The molecular weight at the peak maximum 
(MP) was found to more closely resemble MN than MW suggesting a larger proportion of 
smaller chains. The average chain length varied from 3.6 to 39.9 for FD fractions, while 
it was between 4.7 and 12.1 oligomeric units for CD fractions (Table 15). This implies 
that the chain length range was found to be much greater for FD (~11-fold) than for CD 
(2.5-fold). 
 
 
 
 
 
 
 
Figure 44. Normalized GPC profiles of fractions CD3 through CD30 obtained from 
membrane-based centrifugal filtration of CD mixture.  
A280 refers to the absorbance at 280 nm. The profiles for FD fractions were similar (not shown). 
See Experimental Methods for details. 
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4.4.3 CD and FD are Potent Antagonists of HSV-1 Entry into Cells. 
The ability of CD and FD to prevent the entry of HSV-1 particles into mammalian cells 
was studied using a standard cellular assay.
204-205
 In this assay, HeLa cells were exposed 
to a reporter HSV-1 containing the lacZ gene in the presence and absence of CD, FD, and 
their size fractionated preparations. The large size and significant anionic character of the 
lignins prevents them from entering the mammalian cell, while the viral particle is 
internalized through the concerted action of multiple cellular receptors, including 
HS.
202,203
 Assuming CD and FD mimic cell-membrane-bound HS, the lignins would 
competitively reduce the levels of the virus internalized by HeLa cells. Thus, the β-
galactosidase activity of the internalized HSV-1 serves as a measure of the activity of 
lignins in preventing viral entry. 
 
 
 
 
 
 
 
 
 
 
Figure 45. Profile of HSV-1 entry into cells in the presence of FD3 (A) and CD5 (B) using a 
β-galactosidase activity-based viral entry assay. 
Profiles of other fractions were similar and not shown. IC50 values calculated from these profiles 
are listed in Table 16. See Experimental Methods for details. 
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Figure 45 shows the viral entry profile for two representative lignin fractions, FD3 and 
CD5. The profiles for other fractions were similar (not shown). A concentration-
dependent antagonism of entry of HSV-1 into HeLa was noted for all preparations, which 
was fitted using the standard dose-response equation to calculate the concentration of 
carboxylated lignin required for 50% antagonism (IC50; Table 16). For size-fractioned 
carboxylated lignins FD and CD, the IC50 values were found to be in the range of 72 and 
284 ng/mL, which correspond to nanomolar potencies (13-56 nM). This indicates that our 
new carboxylated lignin scaffold is highly effective in preventing the entry of HSV-1. 
 
Table 16.  Inhibition of HSV-1 Entry into Mammalian Cells by Size-Fractionated 
Carboxylated Lignins CD and FD
a
 
 
 
 
 
 
 
a
The IC50 values are concentrations of carboxylated lignins that result in 50% reduction in level of 
HSV-1 entry. IC50 and HC values were obtained through nonlinear regression analysis of viral 
entry data in the presence and absence of carboxylated lignins (see Experimental Methods). 
b
Calculated using MW values from Table 15. 
c
Errors represent ±2 S.E. 
 
 
A closer look reveals that FD fractions are typically more potent than corresponding CD 
fractions (Table 16). For example, FD3 is approximately 2-fold more potent than CD3. 
Another difference between the two polymers appears in the Hill Cooperativity indices. 
Whereas FD fractions display a HC of ~1, CD fractions show a value of ~0.5. In a 
traditional multisite interaction of a macromolecule with its receptor, HC corresponds to 
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cooperativity of interaction. A value of 1.0 implies no cooperativity, while values less 
than 1.0 imply negative cooperativity. It is difficult to ascribe the phenomenon of 
cooperativity in the antagonism of HSV-1 by CD and FD because both are heterogeneous 
and polydisperse. Rather, HC values may reflect the degree of structural complexity of 
the mixture, which can generate many different types of ligand – receptor complexes. 
This possibility is greater for CD due to the presence of an additional -OH group that is 
known to be more reactive than the corresponding -OMe in FD. 
 
The potency of inhibition is minimally affected for FD fractions despite the change in 
their molecular weights. For example, FD3 exhibits an IC50 of 13 nM, which is not 
different from the value of 17 nM for FD30, although the average chain length increases 
nearly 11-fold. The results for CD fractions are similar. Although the IC50 increases from 
29 nM for the CD3 to 56 nM for CD10 and then decreases to 17 nM for CD30 (Table 
16), the apparently nonlinear change is most likely due to its greater heterogeneity. 
 
The viral inhibition profile of nonsulfated carboxylated lignins is dramatically different 
from that of the sulfated lignins. For sulfated lignins, as the average chain length 
increased so did their ability to antagonize viral entry.
123,206
 The reason for this size 
dependence is the well-known statistical advantage offered by multiple binding sites 
likely to be present in longer polymers. Yet, size-dependence is nearly completely 
eliminated for carboxylated lignins. This implies that even the smallest FD and CD 
chains are able to effectively prevent HSV-1 entry into cells, an observation that carries 
major pharmaceutical value.  
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4.5 Conclusions 
Although a large number of polymers have been designed to inhibit viral entry into 
mammalian cells, nearly each is a sulfated polysaccharide. Our success with sulfated 
lignins led to the current work on carboxylated lignins, which do not contain any sulfate 
group. The two enzymatically synthesized carboxylated lignins are polymers of 
phenylpropanoid residues connected primarily through β-O-4 and β-5 linkages (figure 
43).
 123-124,188-189
 Other linkages including β-β and 5-5 are also likely. These varying inter-
residue linkages and chain lengths introduce considerable structural heterogeneity in the 
polymeric mixture. Structural heterogeneity is a major impediment in the drug discovery 
process. Yet, it affords a high probability of discovering an initial lead, which may be 
fine-tuned to result in a new pharmaceutical agent. The potent antagonism of HSV-1 
entry into mammalian cells by all FD and CD fractions highlights the importance of 
investigating scaffolds outside of the traditional saccharide scaffolds to discover novel 
pharmaceuticals. 
 
The IC50 value of HSV-1 inhibition by FD and CD fractions range from 8 to 56 nM 
(Table 16). In comparison, our previous study with sulfated lignins demonstrated values 
in the range of 1.7 to 1450 nM. This indicates that most carboxylated lignins are better 
antagonists of HSV-1 infection of cells. More specifically, FD3 (MP = 698 Da) and CD3 
(MP = 854 Da) displayed IC50 of 13 and 29 nM, respectively, which are 50-106-fold 
lower than that found for the smallest sulfated lignin (MP = 1900 Da) earlier. This implies 
that either carboxylated lignins are better at mimicking HS in comparison to sulfated 
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lignins or that these new molecules possess a completely different mechanism of 
antagonism of HSV-1. 
 
A key discovery of this work is the high potency of FD (and CD) irrespective of chain 
length. For example, FD3 is almost as antiviral as FD30 (Table 16). A plausible 
explanation for this observation is that FD possesses discrete structure(s) that induce anti-
HSV-1 activity. The average chain length of FD3 is 3.6. This implies that small, 
carboxylate group containing, FD-based molecules, for example, trimers with molecular 
weight of 582 (194 x 3) are likely to exhibit significant anti-HSV-1 activity. In addition 
to the small size, the presence of carboxylic acid groups in these polymers affords an 
excellent route to design orally bioavailable anti-HSV-1 agents. Orally bioavailable 
designs would contain ester protecting groups, which will undergo nonspecific hydrolysis 
in vivo to release the small, carboxylated lignin-based inhibitor.  
 
The carboxylated lignins studied here have additional advantages over sulfated lignins as 
well as other polysaccharide-based agents. These polymers can be easily synthesized in 
high yields in a fairly consistent manner. Chemical sulfation, on the other hand, is a 
difficult reaction and is typically considerably variable.
207-208
 A large number of structural 
variants of ferulic and caffeic acid monomers are available, which implies that new 
agents can be studied for fine-tuning anti-HSV activity. 
 
Overall, this study puts forward a carboxylated lignin polymer as a potent antagonist of 
HSV-1 entry into mammalian cells. It can be expected that carboxylated lignins also 
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antagonize the entry of other enveloped viruses, for example, HIV-1, dengue, Kaposi’s 
sarcoma-associated herpes virus, and hepatitis C virus. In fact, a review of literature 
suggests that effort to develop carboxylated lignins as anti-HIV agents has been made in 
the past.
209-211
 Interestingly, the carboxylated lignins discussed here are about 1000-fold 
more potent at inhibiting HSV-1 than those studied earlier as anti-HIV agents. The reason 
for this massive selectivity in targeting HSV is not clear at the present time, but in 
combination, the results present the possibility of preparing topical formulations of these 
polymers for preventing infections arising from multiple pathogens. 
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